WO2007029063A2 - Treatment and/or prevention of pervasive developmental disorders - Google Patents
Treatment and/or prevention of pervasive developmental disorders Download PDFInfo
- Publication number
- WO2007029063A2 WO2007029063A2 PCT/IB2006/002068 IB2006002068W WO2007029063A2 WO 2007029063 A2 WO2007029063 A2 WO 2007029063A2 IB 2006002068 W IB2006002068 W IB 2006002068W WO 2007029063 A2 WO2007029063 A2 WO 2007029063A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- receptor
- attention
- perception
- reducing
- Prior art date
Links
- 208000029560 autism spectrum disease Diseases 0.000 title claims abstract description 36
- 208000012202 Pervasive developmental disease Diseases 0.000 title claims abstract description 32
- 238000011282 treatment Methods 0.000 title description 17
- 230000002265 prevention Effects 0.000 title description 2
- 230000015654 memory Effects 0.000 claims abstract description 66
- 230000000946 synaptic effect Effects 0.000 claims abstract description 66
- 239000000203 mixture Substances 0.000 claims abstract description 55
- 230000008447 perception Effects 0.000 claims abstract description 44
- 210000000478 neocortex Anatomy 0.000 claims abstract description 42
- 238000000034 method Methods 0.000 claims abstract description 38
- 208000020706 Autistic disease Diseases 0.000 claims description 54
- 206010003805 Autism Diseases 0.000 claims description 53
- 102000005962 receptors Human genes 0.000 claims description 51
- 108020003175 receptors Proteins 0.000 claims description 51
- 239000003814 drug Substances 0.000 claims description 41
- 230000000903 blocking effect Effects 0.000 claims description 38
- 229940079593 drug Drugs 0.000 claims description 38
- 239000005557 antagonist Substances 0.000 claims description 32
- 210000000225 synapse Anatomy 0.000 claims description 31
- 239000003112 inhibitor Substances 0.000 claims description 30
- 230000014509 gene expression Effects 0.000 claims description 28
- 108090000623 proteins and genes Proteins 0.000 claims description 28
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims description 27
- 230000001965 increasing effect Effects 0.000 claims description 27
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 230000002708 enhancing effect Effects 0.000 claims description 19
- 230000003834 intracellular effect Effects 0.000 claims description 19
- 230000015572 biosynthetic process Effects 0.000 claims description 18
- 206010001497 Agitation Diseases 0.000 claims description 16
- 230000003247 decreasing effect Effects 0.000 claims description 14
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 14
- 230000005764 inhibitory process Effects 0.000 claims description 14
- 239000003623 enhancer Substances 0.000 claims description 12
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 11
- 229960003638 dopamine Drugs 0.000 claims description 11
- 239000003149 muscarinic antagonist Substances 0.000 claims description 10
- 102000004052 somatostatin receptor 2 Human genes 0.000 claims description 10
- 108090000586 somatostatin receptor 2 Proteins 0.000 claims description 10
- 230000003313 weakening effect Effects 0.000 claims description 10
- 230000015556 catabolic process Effects 0.000 claims description 9
- 238000005728 strengthening Methods 0.000 claims description 9
- 230000000848 glutamatergic effect Effects 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 7
- 108090000312 Calcium Channels Proteins 0.000 claims description 7
- 102000003922 Calcium Channels Human genes 0.000 claims description 7
- 201000010374 Down Syndrome Diseases 0.000 claims description 7
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 claims description 7
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 claims description 7
- 102000004257 Potassium Channel Human genes 0.000 claims description 7
- 206010044688 Trisomy 21 Diseases 0.000 claims description 7
- 239000000480 calcium channel blocker Substances 0.000 claims description 7
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 7
- 108020001213 potassium channel Proteins 0.000 claims description 7
- 102100033868 Cannabinoid receptor 1 Human genes 0.000 claims description 6
- 101710187010 Cannabinoid receptor 1 Proteins 0.000 claims description 6
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 5
- 229940044551 receptor antagonist Drugs 0.000 claims description 5
- 239000002464 receptor antagonist Substances 0.000 claims description 5
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 claims description 4
- 102000005157 Somatostatin Human genes 0.000 claims description 4
- 108010056088 Somatostatin Proteins 0.000 claims description 4
- 201000007197 atypical autism Diseases 0.000 claims description 4
- 108010022752 Acetylcholinesterase Proteins 0.000 claims description 3
- 208000036640 Asperger disease Diseases 0.000 claims description 3
- 201000006062 Asperger syndrome Diseases 0.000 claims description 3
- 102000015554 Dopamine receptor Human genes 0.000 claims description 3
- 108050004812 Dopamine receptor Proteins 0.000 claims description 3
- 208000001914 Fragile X syndrome Diseases 0.000 claims description 3
- 208000036626 Mental retardation Diseases 0.000 claims description 3
- 102000028517 Neuropeptide receptor Human genes 0.000 claims description 3
- 108070000018 Neuropeptide receptor Proteins 0.000 claims description 3
- 108010077641 Nogo Proteins Proteins 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 102100029831 Reticulon-4 Human genes 0.000 claims description 3
- 208000006289 Rett Syndrome Diseases 0.000 claims description 3
- 102000004874 Synaptophysin Human genes 0.000 claims description 3
- 108090001076 Synaptophysin Proteins 0.000 claims description 3
- 229940022698 acetylcholinesterase Drugs 0.000 claims description 3
- 230000028436 dopamine uptake Effects 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229940044601 receptor agonist Drugs 0.000 claims description 3
- 239000000018 receptor agonist Substances 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 3
- 229960000553 somatostatin Drugs 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 102000012440 Acetylcholinesterase Human genes 0.000 claims 2
- 102000001068 Neural Cell Adhesion Molecules Human genes 0.000 claims 2
- 108010057417 polysialyl neural cell adhesion molecule Proteins 0.000 claims 2
- 210000002569 neuron Anatomy 0.000 description 41
- 210000004027 cell Anatomy 0.000 description 36
- 230000000638 stimulation Effects 0.000 description 32
- 230000003935 attention Effects 0.000 description 29
- 210000004556 brain Anatomy 0.000 description 29
- 241001465754 Metazoa Species 0.000 description 28
- 241000700159 Rattus Species 0.000 description 28
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 27
- 230000004044 response Effects 0.000 description 25
- 210000002763 pyramidal cell Anatomy 0.000 description 23
- 238000012360 testing method Methods 0.000 description 21
- 230000000694 effects Effects 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 18
- 230000013016 learning Effects 0.000 description 18
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 17
- 239000000872 buffer Substances 0.000 description 17
- 239000011575 calcium Substances 0.000 description 17
- 229910052791 calcium Inorganic materials 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 17
- 229910001424 calcium ion Inorganic materials 0.000 description 16
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 14
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 13
- 239000000556 agonist Substances 0.000 description 13
- -1 2-Diethylaminoethyl Chemical group 0.000 description 12
- 102000014649 NMDA glutamate receptor activity proteins Human genes 0.000 description 12
- 210000001176 projection neuron Anatomy 0.000 description 12
- 108091006146 Channels Proteins 0.000 description 11
- 230000003542 behavioural effect Effects 0.000 description 11
- 230000002964 excitative effect Effects 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 230000007246 mechanism Effects 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 210000004092 somatosensory cortex Anatomy 0.000 description 10
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 10
- 229960000604 valproic acid Drugs 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 description 9
- 108010038912 Retinoid X Receptors Proteins 0.000 description 9
- 230000001423 neocortical effect Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 230000005856 abnormality Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 8
- 230000001960 triggered effect Effects 0.000 description 8
- 102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 230000003750 conditioning effect Effects 0.000 description 7
- 230000005284 excitation Effects 0.000 description 7
- 108091008634 hepatocyte nuclear factors 4 Proteins 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 230000026731 phosphorylation Effects 0.000 description 7
- 238000006366 phosphorylation reaction Methods 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- 241000945470 Arcturus Species 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 238000000692 Student's t-test Methods 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 239000006180 TBST buffer Substances 0.000 description 6
- 230000036982 action potential Effects 0.000 description 6
- 230000008033 biological extinction Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000006390 fear memory Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 230000001242 postsynaptic effect Effects 0.000 description 6
- 230000001953 sensory effect Effects 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 238000012549 training Methods 0.000 description 6
- UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 5
- 102000004310 Ion Channels Human genes 0.000 description 5
- 108090000862 Ion Channels Proteins 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 230000009460 calcium influx Effects 0.000 description 5
- 239000003638 chemical reducing agent Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 229930195712 glutamate Natural products 0.000 description 5
- 229940049906 glutamate Drugs 0.000 description 5
- 230000001771 impaired effect Effects 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 238000002493 microarray Methods 0.000 description 5
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 230000035939 shock Effects 0.000 description 5
- 229910000162 sodium phosphate Inorganic materials 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000003956 synaptic plasticity Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- 108010039627 Aprotinin Proteins 0.000 description 4
- 208000012239 Developmental disease Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 description 4
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 description 4
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 4
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
- 229960004373 acetylcholine Drugs 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 229960004405 aprotinin Drugs 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 101150056237 creB gene Proteins 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 210000001320 hippocampus Anatomy 0.000 description 4
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 4
- 108010052968 leupeptin Proteins 0.000 description 4
- 230000020796 long term synaptic depression Effects 0.000 description 4
- 230000027928 long-term synaptic potentiation Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 229950000964 pepstatin Drugs 0.000 description 4
- 108010091212 pepstatin Proteins 0.000 description 4
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 210000002442 prefrontal cortex Anatomy 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000024188 startle response Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 3
- VOROEQBFPPIACJ-SCSAIBSYSA-N (2r)-2-amino-5-phosphonopentanoic acid Chemical compound OC(=O)[C@H](N)CCCP(O)(O)=O VOROEQBFPPIACJ-SCSAIBSYSA-N 0.000 description 3
- UBRKDAVQCKZSPO-UHFFFAOYSA-N 11-[2-[2-(diethylaminomethyl)-1-piperidinyl]-1-oxoethyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one Chemical compound CCN(CC)CC1CCCCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 UBRKDAVQCKZSPO-UHFFFAOYSA-N 0.000 description 3
- 102000003678 AMPA Receptors Human genes 0.000 description 3
- 108090000078 AMPA Receptors Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 3
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 3
- 238000010826 Nissl staining Methods 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 102000019027 Ryanodine Receptor Calcium Release Channel Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 210000003050 axon Anatomy 0.000 description 3
- 210000005056 cell body Anatomy 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 210000001787 dendrite Anatomy 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000000763 evoking effect Effects 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 210000001153 interneuron Anatomy 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 102000006239 metabotropic receptors Human genes 0.000 description 3
- 108020004083 metabotropic receptors Proteins 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000002474 noradrenergic effect Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 230000006977 prepulse inhibition Effects 0.000 description 3
- 230000003518 presynaptic effect Effects 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 108091052345 ryanodine receptor (TC 1.A.3.1) family Proteins 0.000 description 3
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 3
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- NHVRIDDXGZPJTJ-UHFFFAOYSA-N skf-97,541 Chemical compound CP(O)(=O)CCCN NHVRIDDXGZPJTJ-UHFFFAOYSA-N 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 230000005062 synaptic transmission Effects 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 3
- UCKHICKHGAOGAP-UONOGXRCSA-N (2R,4S)-4-[[anilino(oxo)methyl]amino]-5,7-dichloro-1,2,3,4-tetrahydroquinoline-2-carboxylic acid Chemical compound N([C@H]1C[C@@H](NC2=CC(Cl)=CC(Cl)=C21)C(=O)O)C(=O)NC1=CC=CC=C1 UCKHICKHGAOGAP-UONOGXRCSA-N 0.000 description 2
- MYDMWESTDPJANS-ZCFIWIBFSA-N (2r)-2-amino-7-phosphonoheptanoic acid Chemical compound OC(=O)[C@H](N)CCCCCP(O)(O)=O MYDMWESTDPJANS-ZCFIWIBFSA-N 0.000 description 2
- OKJBLHIYOWSQDJ-VIFPVBQESA-N (2s)-2-amino-3-(4-hexyl-3-oxo-1,2-oxazol-5-yl)propanoic acid Chemical compound CCCCCCC1=C(C[C@H](N)C(O)=O)ONC1=O OKJBLHIYOWSQDJ-VIFPVBQESA-N 0.000 description 2
- VOROEQBFPPIACJ-BYPYZUCNSA-N (2s)-2-azaniumyl-5-phosphonopentanoate Chemical compound OC(=O)[C@@H](N)CCCP(O)(O)=O VOROEQBFPPIACJ-BYPYZUCNSA-N 0.000 description 2
- DNCAZYRLRMTVSF-JTQLQIEISA-N (S)-alpha-methyl-4-carboxyphenylglycine Chemical compound OC(=O)[C@](N)(C)C1=CC=C(C(O)=O)C=C1 DNCAZYRLRMTVSF-JTQLQIEISA-N 0.000 description 2
- JCJDLPUASJEVRN-UHFFFAOYSA-N 2-(3,3-diphenylpropylamino)acetamide;hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CCNCC(=O)N)C1=CC=CC=C1 JCJDLPUASJEVRN-UHFFFAOYSA-N 0.000 description 2
- CLPOJGPBUGCUKT-UHFFFAOYSA-N 2-amino-2-(2-chlorophenyl)cyclohexan-1-one;hydrochloride Chemical compound Cl.C=1C=CC=C(Cl)C=1C1(N)CCCCC1=O CLPOJGPBUGCUKT-UHFFFAOYSA-N 0.000 description 2
- LBTABPSJONFLPO-UHFFFAOYSA-N 2-amino-3-phosphonopropanoic acid Chemical compound OC(=O)C(N)CP(O)(O)=O LBTABPSJONFLPO-UHFFFAOYSA-N 0.000 description 2
- PKDHDJBNEKXCBI-UHFFFAOYSA-N 2-methyl-6-(phenylethynyl)pyridine hydrochloride Chemical compound Cl.CC1=CC=CC(C#CC=2C=CC=CC=2)=N1 PKDHDJBNEKXCBI-UHFFFAOYSA-N 0.000 description 2
- CXIHLPLRTFPHKX-UHFFFAOYSA-N 3-amino-6-chloro-5-(dimethylamino)-n-pyridin-3-ylpyrazine-2-carboxamide;hydrochloride Chemical compound Cl.N1=C(Cl)C(N(C)C)=NC(N)=C1C(=O)NC1=CC=CN=C1 CXIHLPLRTFPHKX-UHFFFAOYSA-N 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 2
- DNCAZYRLRMTVSF-UHFFFAOYSA-N 4-(1-amino-1-carboxyethyl)benzoic acid Chemical compound OC(=O)C(N)(C)C1=CC=C(C(O)=O)C=C1 DNCAZYRLRMTVSF-UHFFFAOYSA-N 0.000 description 2
- AIEFWRHRHFRLFT-UHFFFAOYSA-N 4-(1-amino-1-carboxypropyl)benzoic acid Chemical compound CCC(N)(C(O)=O)C1=CC=C(C(O)=O)C=C1 AIEFWRHRHFRLFT-UHFFFAOYSA-N 0.000 description 2
- SGIKDIUCJAUSRD-QMMMGPOBSA-N 4-[(s)-amino(carboxy)methyl]-3-methylbenzoic acid Chemical compound CC1=CC(C(O)=O)=CC=C1[C@H](N)C(O)=O SGIKDIUCJAUSRD-QMMMGPOBSA-N 0.000 description 2
- BGKFPRIGXAVYNX-UHFFFAOYSA-N 5,7-dichloro-4-oxo-1H-quinoline-2-carboxylic acid Chemical compound ClC1=CC(Cl)=CC2=NC(C(=O)O)=CC(O)=C21 BGKFPRIGXAVYNX-UHFFFAOYSA-N 0.000 description 2
- UAWVRVFHMOSAPU-UHFFFAOYSA-N 7-chlorokynurenic acid Chemical compound C1=CC(Cl)=CC2=NC(C(=O)O)=CC(O)=C21 UAWVRVFHMOSAPU-UHFFFAOYSA-N 0.000 description 2
- KPYSYYIEGFHWSV-QMMMGPOBSA-N Arbaclofen Chemical compound OC(=O)C[C@@H](CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-QMMMGPOBSA-N 0.000 description 2
- 241000796533 Arna Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- MMWCIQZXVOZEGG-XJTPDSDZSA-N D-myo-Inositol 1,4,5-trisphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H](O)[C@@H]1OP(O)(O)=O MMWCIQZXVOZEGG-XJTPDSDZSA-N 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 108090000420 L-Type Calcium Channels Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 2
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 2
- 108090000699 N-Type Calcium Channels Proteins 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 238000001190 Q-PCR Methods 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 2
- INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 2
- DLHMKHREUTXMCH-UHFFFAOYSA-N [2-(2,6-dimethylanilino)-2-oxoethyl]-triethylazanium;bromide Chemical compound [Br-].CC[N+](CC)(CC)CC(=O)NC1=C(C)C=CC=C1C DLHMKHREUTXMCH-UHFFFAOYSA-N 0.000 description 2
- DOQPXTMNIUCOSY-UHFFFAOYSA-N [4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl]-[2-(3,4-dimethoxyphenyl)ethyl]-methylazanium;chloride Chemical compound [H+].[Cl-].C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 DOQPXTMNIUCOSY-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 229940124277 aminobutyric acid Drugs 0.000 description 2
- 238000012197 amplification kit Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000000561 anti-psychotic effect Effects 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 239000008228 bacteriostatic water for injection Substances 0.000 description 2
- MOLPUWBMSBJXER-YDGSQGCISA-N bilobalide Chemical compound O([C@H]1OC2=O)C(=O)[C@H](O)[C@@]11[C@@](C(C)(C)C)(O)C[C@H]3[C@@]21CC(=O)O3 MOLPUWBMSBJXER-YDGSQGCISA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 230000003185 calcium uptake Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 239000013256 coordination polymer Substances 0.000 description 2
- 229940095074 cyclic amp Drugs 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- IJVMOGKBEVRBPP-ZETCQYMHSA-N dcpg Chemical compound OC(=O)[C@@H](N)C1=CC=C(C(O)=O)C(C(O)=O)=C1 IJVMOGKBEVRBPP-ZETCQYMHSA-N 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 150000001982 diacylglycerols Chemical class 0.000 description 2
- 238000001152 differential interference contrast microscopy Methods 0.000 description 2
- HDRXZJPWHTXQRI-BHDTVMLSSA-N diltiazem hydrochloride Chemical compound [Cl-].C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CC[NH+](C)C)C2=CC=CC=C2S1 HDRXZJPWHTXQRI-BHDTVMLSSA-N 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000002222 downregulating effect Effects 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002461 excitatory amino acid Effects 0.000 description 2
- 239000003257 excitatory amino acid Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000011536 extraction buffer Substances 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 229960004427 isradipine Drugs 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 230000008449 language Effects 0.000 description 2
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003551 muscarinic effect Effects 0.000 description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
- 229960001597 nifedipine Drugs 0.000 description 2
- 229960000715 nimodipine Drugs 0.000 description 2
- 230000036963 noncompetitive effect Effects 0.000 description 2
- 229950011198 otenzepad Drugs 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000011458 pharmacological treatment Methods 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229950007002 phosphocreatine Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 2
- 239000004224 potassium gluconate Substances 0.000 description 2
- 229960003189 potassium gluconate Drugs 0.000 description 2
- 235000013926 potassium gluconate Nutrition 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000003997 social interaction Effects 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 230000006886 spatial memory Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000003656 tris buffered saline Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- QLTXKCWMEZIHBJ-WLHGVMLRSA-N (-)-mk-801 hydrogen maleate Chemical compound OC(=O)\C=C\C(O)=O.C12=CC=CC=C2C2(C)C3=CC=CC=C3CC1N2 QLTXKCWMEZIHBJ-WLHGVMLRSA-N 0.000 description 1
- FPXPIEZPAXSELW-REIIWYCASA-N (1aR,7E,7aR)-7-hydroxyimino-N-phenyl-1,7a-dihydrocyclopropa[b]chromene-1a-carboxamide Chemical compound O=C([C@@]12C[C@@H]1\C(C1=CC=CC=C1O2)=N/O)NC1=CC=CC=C1 FPXPIEZPAXSELW-REIIWYCASA-N 0.000 description 1
- FERIKTBTNCSGJS-OBLUMXEWSA-N (1r,2s)-4-aminocyclopentane-1,2,4-tricarboxylic acid Chemical compound OC(=O)C1(N)C[C@H](C(O)=O)[C@H](C(O)=O)C1 FERIKTBTNCSGJS-OBLUMXEWSA-N 0.000 description 1
- BOJYRNFSHPAZBL-UHFFFAOYSA-N (2-bromothiophen-3-yl)methanol Chemical compound OCC=1C=CSC=1Br BOJYRNFSHPAZBL-UHFFFAOYSA-N 0.000 description 1
- VBRJFXSFCYEZMQ-HNNXBMFYSA-N (2s)-2-amino-3-[3-(2-chlorophenyl)-5-(phosphonomethyl)phenyl]propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC(CP(O)(O)=O)=CC(C=2C(=CC=CC=2)Cl)=C1 VBRJFXSFCYEZMQ-HNNXBMFYSA-N 0.000 description 1
- NYZFUZCCDOSQBG-AWEZNQCLSA-N (2s)-2-amino-3-[5-(2,4-dichlorophenyl)-2-hydroxy-3-(phosphonomethyl)phenyl]propanoic acid Chemical compound OP(=O)(O)CC1=C(O)C(C[C@H](N)C(O)=O)=CC(C=2C(=CC(Cl)=CC=2)Cl)=C1 NYZFUZCCDOSQBG-AWEZNQCLSA-N 0.000 description 1
- XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
- HJVCHYDYCYBBQX-HLTLHRPFSA-N (2s,3s,4e,6e,8s,9s)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid Chemical compound OC(=O)[C@@H](C)[C@@H](N)/C=C/C(/C)=C/[C@H](C)[C@@H](OC)CC1=CC=CC=C1 HJVCHYDYCYBBQX-HLTLHRPFSA-N 0.000 description 1
- HCKUBNLZMKAEIN-VKHMYHEASA-N (3s)-3-amino-1-hydroxypyrrolidin-2-one Chemical compound N[C@H]1CCN(O)C1=O HCKUBNLZMKAEIN-VKHMYHEASA-N 0.000 description 1
- ZFLWDHHVRRZMEI-CYBMUJFWSA-N (4R)-2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylic acid methyl ester Chemical compound COC(=O)C1=C(C)NC(C)=C([N+]([O-])=O)[C@@H]1C1=CC=CC=C1C(F)(F)F ZFLWDHHVRRZMEI-CYBMUJFWSA-N 0.000 description 1
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
- BDYHNCZIGYIOGJ-DUXPYHPUSA-N (e)-2-amino-4-methyl-5-phosphonopent-3-enoic acid Chemical compound OP(=O)(O)CC(/C)=C/C(N)C(O)=O BDYHNCZIGYIOGJ-DUXPYHPUSA-N 0.000 description 1
- BHXGTFUQDGMXHA-BTJKTKAUSA-N (z)-but-2-enedioic acid;(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 2-(4-chlorophenoxy)butanoate Chemical compound OC(=O)\C=C/C(O)=O.C1C(N2C)CCC2CC1OC(=O)C(CC)OC1=CC=C(Cl)C=C1 BHXGTFUQDGMXHA-BTJKTKAUSA-N 0.000 description 1
- JKLLCRVPQXFAJU-UHFFFAOYSA-N 1,2-benzodiazepin-6-one dihydrochloride Chemical compound Cl.Cl.O=c1cccc2nncccc12 JKLLCRVPQXFAJU-UHFFFAOYSA-N 0.000 description 1
- FHGWEHGZBUBQKL-UHFFFAOYSA-N 1,2-benzothiazepine Chemical compound S1N=CC=CC2=CC=CC=C12 FHGWEHGZBUBQKL-UHFFFAOYSA-N 0.000 description 1
- DOFXKPAOJLLPII-UHFFFAOYSA-M 1,3-di(propan-2-yl)imidazol-1-ium;chloride Chemical compound [Cl-].CC(C)N1C=C[N+](C(C)C)=C1 DOFXKPAOJLLPII-UHFFFAOYSA-M 0.000 description 1
- MMWCIQZXVOZEGG-UHFFFAOYSA-N 1,4,5-IP3 Natural products OC1C(O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(O)C1OP(O)(O)=O MMWCIQZXVOZEGG-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- GGUSQTSTQSHJAH-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-[4-(4-fluorobenzyl)piperidin-1-yl]ethanol Chemical compound C=1C=C(Cl)C=CC=1C(O)CN(CC1)CCC1CC1=CC=C(F)C=C1 GGUSQTSTQSHJAH-UHFFFAOYSA-N 0.000 description 1
- FVTVMQPGKVHSEY-UHFFFAOYSA-N 1-AMINOCYCLOBUTANE CARBOXYLIC ACID Chemical compound OC(=O)C1(N)CCC1 FVTVMQPGKVHSEY-UHFFFAOYSA-N 0.000 description 1
- KBPZBOSJIZEELA-UHFFFAOYSA-N 1-[2-[4-methoxy-3-[3-(4-methoxyphenyl)propoxy]phenyl]ethyl]imidazole;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1CCCOC1=CC(CCN2C=NC=C2)=CC=C1OC KBPZBOSJIZEELA-UHFFFAOYSA-N 0.000 description 1
- XZVKOMOTDZLLDN-UHFFFAOYSA-N 1-methyl-10-[2-(4-methylpiperazin-1-yl)acetyl]-5h-thieno[3,4-b][1,5]benzodiazepin-4-one;hydrochloride Chemical compound Cl.C1CN(C)CCN1CC(=O)N1C2=CC=CC=C2NC(=O)C2=CSC(C)=C21 XZVKOMOTDZLLDN-UHFFFAOYSA-N 0.000 description 1
- FHVUTHWUIUXZBY-QLANQDRJSA-N 147794-23-8 Chemical compound C([C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]2C(=O)N[C@@H]3C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC2)C(N)=O)=O)CSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSSC3)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(N1)=O)CCSC)[C@@H](C)O)C1=CC=C(O)C=C1 FHVUTHWUIUXZBY-QLANQDRJSA-N 0.000 description 1
- UQNAFPHGVPVTAL-UHFFFAOYSA-N 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline Chemical compound N1C(=O)C(=O)NC2=C1C=C([N+]([O-])=O)C1=C2C=CC=C1S(=O)(=O)N UQNAFPHGVPVTAL-UHFFFAOYSA-N 0.000 description 1
- IAWXTSMHXFRLQR-UHFFFAOYSA-N 2,3-bis($l^{1}-oxidanyl)-7-nitroquinoxaline-6-carbonitrile Chemical compound O=C1C(=O)N=C2C=C(C#N)C([N+](=O)[O-])=CC2=N1 IAWXTSMHXFRLQR-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- XWQWACGTGFICFO-UHFFFAOYSA-N 2-(diethylamino)ethyl 1-(4-nitrophenyl)cyclopentane-1-carboxylate;hydrochloride Chemical compound Cl.C=1C=C([N+]([O-])=O)C=CC=1C1(C(=O)OCCN(CC)CC)CCCC1 XWQWACGTGFICFO-UHFFFAOYSA-N 0.000 description 1
- FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical compound OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 description 1
- OKJBLHIYOWSQDJ-UHFFFAOYSA-N 2-amino-3-(4-hexyl-3-oxo-1,2-oxazol-5-yl)propanoic acid Chemical compound CCCCCCC1=C(CC(N)C(O)=O)ONC1=O OKJBLHIYOWSQDJ-UHFFFAOYSA-N 0.000 description 1
- MYDMWESTDPJANS-UHFFFAOYSA-N 2-amino-7-phosphonoheptanoic acid Chemical compound OC(=O)C(N)CCCCCP(O)(O)=O MYDMWESTDPJANS-UHFFFAOYSA-N 0.000 description 1
- HYQMIUSWZXGTCC-UHFFFAOYSA-N 2-amino-n-(1,2-diphenylpropan-2-yl)acetamide;hydron;chloride Chemical compound Cl.C=1C=CC=CC=1C(C)(NC(=O)CN)CC1=CC=CC=C1 HYQMIUSWZXGTCC-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- DZRJZDQAGMZGGA-UHFFFAOYSA-L 3-(1,3-dioxoisoindol-2-yl)propyl-[6-[3-(1,3-dioxoisoindol-2-yl)propyl-dimethylazaniumyl]hexyl]-dimethylazanium;dibromide Chemical compound [Br-].[Br-].O=C1C2=CC=CC=C2C(=O)N1CCC[N+](C)(C)CCCCCC[N+](C)(C)CCCN1C(=O)C2=CC=CC=C2C1=O DZRJZDQAGMZGGA-UHFFFAOYSA-L 0.000 description 1
- 239000003483 4 aminobutyric acid A receptor stimulating agent Substances 0.000 description 1
- 239000003185 4 aminobutyric acid B receptor stimulating agent Substances 0.000 description 1
- WWJHRSCUAQPFQO-UHFFFAOYSA-M 4-DAMP methiodide Chemical compound [I-].C1C[N+](C)(C)CCC1OC(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 WWJHRSCUAQPFQO-UHFFFAOYSA-M 0.000 description 1
- GXZSAQLJWLCLOX-ZETCQYMHSA-N 4-[(s)-amino(carboxy)methyl]-2-hydroxybenzoic acid Chemical compound OC(=O)[C@@H](N)C1=CC=C(C(O)=O)C(O)=C1 GXZSAQLJWLCLOX-ZETCQYMHSA-N 0.000 description 1
- UYNVMODNBIQBMV-UHFFFAOYSA-N 4-[1-hydroxy-2-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 UYNVMODNBIQBMV-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- CQTDZUSQSTUZDA-UHFFFAOYSA-M 5-(1-adamantylmethylamino)pentyl-trimethylazanium;bromide;hydrobromide Chemical compound Br.[Br-].C1C(C2)CC3CC2CC1(CNCCCCC[N+](C)(C)C)C3 CQTDZUSQSTUZDA-UHFFFAOYSA-M 0.000 description 1
- MHOSUIMBPQVOEU-MGDILKBHSA-N 5-o-[3-(4,4-diphenylpiperidin-1-yl)propyl] 3-o-methyl (4r)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate;hydrochloride Chemical compound Cl.C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)OCCCN2CCC(CC2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=CC=CC([N+]([O-])=O)=C1 MHOSUIMBPQVOEU-MGDILKBHSA-N 0.000 description 1
- MHOSUIMBPQVOEU-WAQYZQTGSA-N 5-o-[3-(4,4-diphenylpiperidin-1-yl)propyl] 3-o-methyl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate;hydrochloride Chemical compound Cl.C1([C@@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)OCCCN2CCC(CC2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=CC=CC([N+]([O-])=O)=C1 MHOSUIMBPQVOEU-WAQYZQTGSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- RPXVIAFEQBNEAX-UHFFFAOYSA-N 6-Cyano-7-nitroquinoxaline-2,3-dione Chemical compound N1C(=O)C(=O)NC2=C1C=C([N+](=O)[O-])C(C#N)=C2 RPXVIAFEQBNEAX-UHFFFAOYSA-N 0.000 description 1
- MZDYABXXPZNUCT-OAQYLSRUSA-N AF-DX 384 Chemical compound CCCN(CCC)C[C@H]1CCCCN1CCNC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 MZDYABXXPZNUCT-OAQYLSRUSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102100033639 Acetylcholinesterase Human genes 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102000004145 Annexin A1 Human genes 0.000 description 1
- 108090000663 Annexin A1 Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- IYGYMKDQCDOMRE-QRWMCTBCSA-N Bicculine Chemical compound O([C@H]1C2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-QRWMCTBCSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100263837 Bovine ephemeral fever virus (strain BB7721) beta gene Proteins 0.000 description 1
- MZQQZBPMRPDKTB-JEDNCBNOSA-N CGP 78608 hydrochloride Chemical compound Cl.N1C(=O)C(=O)NC2=C1C=C(Br)C=C2CN[C@H](C)P(O)(O)=O MZQQZBPMRPDKTB-JEDNCBNOSA-N 0.000 description 1
- 229940043709 CaM kinase II inhibitor Drugs 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 102000004646 Calcium-Calmodulin-Dependent Protein Kinase Type 4 Human genes 0.000 description 1
- 108010003613 Calcium-Calmodulin-Dependent Protein Kinase Type 4 Proteins 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 101150029544 Crem gene Proteins 0.000 description 1
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 1
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- ASNFTDCKZKHJSW-UHFFFAOYSA-N DL-Quisqualic acid Natural products OC(=O)C(N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-UHFFFAOYSA-N 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 101100316840 Enterobacteria phage P4 Beta gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 229940122236 Histamine receptor antagonist Drugs 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000004016 L-Type Calcium Channels Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 208000020358 Learning disease Diseases 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102100038354 Metabotropic glutamate receptor 4 Human genes 0.000 description 1
- 102100037636 Metabotropic glutamate receptor 8 Human genes 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- 102000004129 N-Type Calcium Channels Human genes 0.000 description 1
- BAQMYDQNMFBZNA-UHFFFAOYSA-N N-biotinyl-L-lysine Natural products N1C(=O)NC2C(CCCCC(=O)NCCCCC(N)C(O)=O)SCC21 BAQMYDQNMFBZNA-UHFFFAOYSA-N 0.000 description 1
- 108020002076 NR2 subfamily Proteins 0.000 description 1
- 102000038100 NR2 subfamily Human genes 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241001290721 Odontonema tubiforme Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010075750 P-Type Calcium Channels Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- KIDHWZJUCRJVML-UHFFFAOYSA-N Putrescine Natural products NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 1
- 108010027023 Q-Type Calcium Channels Proteins 0.000 description 1
- ASNFTDCKZKHJSW-REOHCLBHSA-N Quisqualic acid Chemical compound OC(=O)[C@@H](N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-REOHCLBHSA-N 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- FYJZEHCQSUBZDY-SEELMCCHSA-N Ro 25-6981 maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@H](C)[C@@H](O)C=1C=CC(O)=CC=1)N(CC1)CCC1CC1=CC=CC=C1 FYJZEHCQSUBZDY-SEELMCCHSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229930001406 Ryanodine Natural products 0.000 description 1
- LPMRCCNDNGONCD-RITPCOANSA-N Selfotel Chemical compound OC(=O)[C@@H]1C[C@H](CP(O)(O)=O)CCN1 LPMRCCNDNGONCD-RITPCOANSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FUUPFUIGNBPCAY-BYPYZUCNSA-N [(2s)-3-amino-2-hydroxypropyl]-methylphosphinic acid Chemical compound CP(O)(=O)C[C@@H](O)CN FUUPFUIGNBPCAY-BYPYZUCNSA-N 0.000 description 1
- YYBNDIVPHIWTPK-KYJQVDHRSA-N [(3as,8bs)-3,4,8b-trimethyl-1,2,3,3a-tetrahydropyrrolo[2,3-b]indol-3-ium-7-yl] n-methylcarbamate;sulfate Chemical compound [O-]S([O-])(=O)=O.C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CC[NH+]2C.C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CC[NH+]2C YYBNDIVPHIWTPK-KYJQVDHRSA-N 0.000 description 1
- OKDOWCKDTWNRCB-GQCTYLIASA-N [(e)-4-amino-5-ethoxy-2-methyl-5-oxopent-2-enyl]phosphonic acid Chemical compound CCOC(=O)C(N)\C=C(/C)CP(O)(O)=O OKDOWCKDTWNRCB-GQCTYLIASA-N 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 1
- PCBMYXLJUKBODW-UHFFFAOYSA-N [Ru].ClOCl Chemical compound [Ru].ClOCl PCBMYXLJUKBODW-UHFFFAOYSA-N 0.000 description 1
- RWTGFMPOODRXIM-UHFFFAOYSA-N [n'-[4-[[amino(azaniumyl)methylidene]amino]butyl]carbamimidoyl]azanium;sulfate Chemical compound [O-]S([O-])(=O)=O.NC([NH3+])=NCCCCN=C(N)[NH3+] RWTGFMPOODRXIM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- CGWVBPMMLKULCR-UHFFFAOYSA-N acetic acid;cyclohexylmethanamine Chemical compound CC(O)=O.NCC1CCCCC1 CGWVBPMMLKULCR-UHFFFAOYSA-N 0.000 description 1
- AXJDEHNQPMZKOS-UHFFFAOYSA-N acetylazanium;chloride Chemical compound [Cl-].CC([NH3+])=O AXJDEHNQPMZKOS-UHFFFAOYSA-N 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 description 1
- 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 1
- DXUUXWKFVDVHIK-UHFFFAOYSA-N ambenonium chloride Chemical compound [Cl-].[Cl-].C=1C=CC=C(Cl)C=1C[N+](CC)(CC)CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl DXUUXWKFVDVHIK-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012122 aqueous mounting media Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- GOOXRYWLNNXLFL-UHFFFAOYSA-H azane oxygen(2-) ruthenium(3+) ruthenium(4+) hexachloride Chemical compound N.N.N.N.N.N.N.N.N.N.N.N.N.N.[O--].[O--].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Ru+3].[Ru+3].[Ru+4] GOOXRYWLNNXLFL-UHFFFAOYSA-H 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical group N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- UIEATEWHFDRYRU-UHFFFAOYSA-N bepridil Chemical compound C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 UIEATEWHFDRYRU-UHFFFAOYSA-N 0.000 description 1
- 229960003665 bepridil Drugs 0.000 description 1
- HMQPEDMEOBLSQB-RPHKZZMBSA-N beta-D-Galp-(1->3)-D-GlcpNAc Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HMQPEDMEOBLSQB-RPHKZZMBSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- AACMFFIUYXGCOC-UHFFFAOYSA-N bicuculline Natural products CN1CCc2cc3OCOc3cc2C1C4OCc5c6OCOc6ccc45 AACMFFIUYXGCOC-UHFFFAOYSA-N 0.000 description 1
- BAQMYDQNMFBZNA-MNXVOIDGSA-N biocytin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCC[C@H](N)C(O)=O)SC[C@@H]21 BAQMYDQNMFBZNA-MNXVOIDGSA-N 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000028956 calcium-mediated signaling Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- BDYHNCZIGYIOGJ-XWCPEMDWSA-N cgp-37849 Chemical compound OP(=O)(O)CC(/C)=C/[C@@H](N)C(O)=O BDYHNCZIGYIOGJ-XWCPEMDWSA-N 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- LOCPVWIREQIGNQ-UHFFFAOYSA-N chembl88553 Chemical compound CC1=CC=C(O)C(N=NC=2C=CC=CC=2)=N1 LOCPVWIREQIGNQ-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000006949 cholinergic function Effects 0.000 description 1
- 230000019113 chromatin silencing Effects 0.000 description 1
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 1
- 229960005132 cisapride Drugs 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000037411 cognitive enhancing Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- IYGYMKDQCDOMRE-UHFFFAOYSA-N d-Bicucullin Natural products CN1CCC2=CC=3OCOC=3C=C2C1C1OC(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-UHFFFAOYSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000007673 developmental toxicity Effects 0.000 description 1
- 231100000415 developmental toxicity Toxicity 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 229960005316 diltiazem hydrochloride Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- YCXDDPGRZKUGDG-UHFFFAOYSA-L disodium;6-cyano-7-nitroquinoxaline-2,3-diolate Chemical compound [Na+].[Na+].N#CC1=C([N+]([O-])=O)C=C2N=C([O-])C([O-])=NC2=C1 YCXDDPGRZKUGDG-UHFFFAOYSA-L 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 208000018459 dissociative disease Diseases 0.000 description 1
- LBOJYSIDWZQNJS-CVEARBPZSA-N dizocilpine Chemical compound C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 LBOJYSIDWZQNJS-CVEARBPZSA-N 0.000 description 1
- 229950004794 dizocilpine Drugs 0.000 description 1
- QLTXKCWMEZIHBJ-PJGJYSAQSA-N dizocilpine maleate Chemical compound OC(=O)\C=C/C(O)=O.C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 QLTXKCWMEZIHBJ-PJGJYSAQSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229950005455 eliprodil Drugs 0.000 description 1
- 108010036895 endo-alpha-sialidase Proteins 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 102000012803 ephrin Human genes 0.000 description 1
- 108060002566 ephrin Proteins 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- FXCTZFMSAHZQTR-PFJVYOFESA-N ethyl (1as,7e,7as)-7-hydroxyimino-1,7a-dihydrocyclopropa[b]chromene-1a-carboxylate Chemical compound O\N=C/1C2=CC=CC=C2O[C@]2(C(=O)OCC)[C@H]\1C2 FXCTZFMSAHZQTR-PFJVYOFESA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 229940093476 ethylene glycol Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000002743 euphoric effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960003472 felbamate Drugs 0.000 description 1
- WKGXYQFOCVYPAC-UHFFFAOYSA-N felbamate Chemical compound NC(=O)OCC(COC(N)=O)C1=CC=CC=C1 WKGXYQFOCVYPAC-UHFFFAOYSA-N 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 108091092197 high voltage-gated calcium channel activity Proteins 0.000 description 1
- 102000040854 high voltage-gated calcium channel activity Human genes 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000011539 homogenization buffer Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- ZUFVXZVXEJHHBN-UHFFFAOYSA-N hydron;1,2,3,4-tetrahydroacridin-9-amine;chloride Chemical compound [Cl-].C1=CC=C2C([NH3+])=C(CCCC3)C3=NC2=C1 ZUFVXZVXEJHHBN-UHFFFAOYSA-N 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- MKXZASYAUGDDCJ-CGTJXYLNSA-N levomethorphan Chemical compound C([C@H]12)CCC[C@@]11CCN(C)[C@@H]2CC2=CC=C(OC)C=C21 MKXZASYAUGDDCJ-CGTJXYLNSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- PGYPOBZJRVSMDS-UHFFFAOYSA-N loperamide hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 PGYPOBZJRVSMDS-UHFFFAOYSA-N 0.000 description 1
- 229960002983 loperamide hydrochloride Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- STIRHCNEGQQBOY-QEYWKRMJSA-N ly-235,959 Chemical compound C1[C@@H](CP(O)(O)=O)CC[C@H]2CN[C@H](C(=O)O)C[C@H]21 STIRHCNEGQQBOY-QEYWKRMJSA-N 0.000 description 1
- 229940124807 mGLUR antagonist Drugs 0.000 description 1
- 210000004995 male reproductive system Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 230000007334 memory performance Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 108010038422 metabotropic glutamate receptor 4 Proteins 0.000 description 1
- 108010038448 metabotropic glutamate receptor 8 Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000002811 myosin light chain kinase inhibitor Substances 0.000 description 1
- RTBSNGZUPKLGHZ-UHFFFAOYSA-N n,n'-bis(3-aminopropyl)butane-1,4-diamine;trihydrochloride Chemical compound Cl.Cl.Cl.NCCCNCCCCNCCCN RTBSNGZUPKLGHZ-UHFFFAOYSA-N 0.000 description 1
- QLMQSFIGPVLVAO-UHFFFAOYSA-N n-[3-(azepan-1-yl)propyl]-2-cyclohexyl-2-phenylacetamide;hydrochloride Chemical compound Cl.C1CCCCC1C(C=1C=CC=CC=1)C(=O)NCCCN1CCCCCC1 QLMQSFIGPVLVAO-UHFFFAOYSA-N 0.000 description 1
- DRHUIJOIIKXHEH-UHFFFAOYSA-N n-[3-[4-(3-aminopropylamino)butylamino]propyl]-2-(4-hydroxyphenyl)acetamide Chemical compound NCCCNCCCCNCCCNC(=O)CC1=CC=C(O)C=C1 DRHUIJOIIKXHEH-UHFFFAOYSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- UIAGMCDKSXEBJQ-UHFFFAOYSA-N nimodipine Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-UHFFFAOYSA-N 0.000 description 1
- 229940072101 nimotop Drugs 0.000 description 1
- 229960000227 nisoldipine Drugs 0.000 description 1
- 229960005425 nitrendipine Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- PBLZLIFKVPJDCO-UHFFFAOYSA-N omega-Aminododecanoic acid Natural products NCCCCCCCCCCCC(O)=O PBLZLIFKVPJDCO-UHFFFAOYSA-N 0.000 description 1
- FDQZTPPHJRQRQQ-NZPQQUJLSA-N omega-conotoxin GVIA Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CSSC[C@H]2C(=O)N[C@@H]3C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N4C[C@H](O)C[C@H]4C(=O)N1)=O)CSSC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSSC3)C(=O)N[C@@H](CO)C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N2)=O)[C@H](O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)C1=CC=C(O)C=C1 FDQZTPPHJRQRQQ-NZPQQUJLSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003906 phosphoinositides Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 1
- 229960004633 pirenzepine Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920003207 poly(ethylene-2,6-naphthalate) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000011112 polyethylene naphthalate Substances 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 230000036278 prepulse Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 229940076155 protein modulator Drugs 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000003989 repetitive behavior Effects 0.000 description 1
- 208000013406 repetitive behavior Diseases 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- JJSYXNQGLHBRRK-SFEDZAPPSA-N ryanodine Chemical compound O([C@@H]1[C@]([C@@]2([C@]3(O)[C@]45O[C@@]2(O)C[C@]([C@]4(CC[C@H](C)[C@H]5O)O)(C)[C@@]31O)C)(O)C(C)C)C(=O)C1=CC=CN1 JJSYXNQGLHBRRK-SFEDZAPPSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229960004499 scopolamine hydrobromide Drugs 0.000 description 1
- WTGQALLALWYDJH-MOUKNHLCSA-N scopolamine hydrobromide (anhydrous) Chemical compound Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 WTGQALLALWYDJH-MOUKNHLCSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- SISOFUCTXZKSOQ-ZHACJKMWSA-N sib-1893 Chemical compound CC1=CC=CC(\C=C\C=2C=CC=CC=2)=N1 SISOFUCTXZKSOQ-ZHACJKMWSA-N 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009782 synaptic response Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960003565 tacrine hydrochloride Drugs 0.000 description 1
- 231100000462 teratogen Toxicity 0.000 description 1
- 239000003439 teratogenic agent Substances 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012033 transcriptional gene silencing Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 230000036967 uncompetitive effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 229960000881 verapamil hydrochloride Drugs 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- BPKIMPVREBSLAJ-QTBYCLKRSA-N ziconotide Chemical compound C([C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]2C(=O)N[C@@H]3C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC2)C(N)=O)=O)CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSSC3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(N1)=O)CCSC)[C@@H](C)O)C1=CC=C(O)C=C1 BPKIMPVREBSLAJ-QTBYCLKRSA-N 0.000 description 1
- 229960002811 ziconotide Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
- 108091058553 ω-conotoxin GVIA Proteins 0.000 description 1
- 108091058537 ω-conotoxin MVIIC Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Definitions
- the present invention concerns a method for treating and/or preventing Pervasive Developmental Disorders in a subject in need thereof comprising the step of modulating the synaptic connectivity in the neocortex by administering a therapeutically effective amount of a composition capable of reducing memory, perception and/or attention performance.
- Autism spectrum disorders is now recognized as a major neurological developmental disorder affecting children starting during the first 5 years of life.
- Leo Kanner in 1943, first described children that do not make eye contact, are impaired in language, apparently lack the need or skill for social interaction, indulge in repetitive behavior, display sensory perceptual abnormalities, are extremely sensitive to novel situations or environments displaying a resistance to change, and they do not seek comfort during stress.
- Most autistics also suffer from severe sensory distortions, gastrointestinal and eating disorders as well as sleep, movement, metabolic and immune disorders, and about half experience epileptic episodes. Autism is a broad-spectrum disorder with a wide range of symptoms.
- Classically autism is considered to be on one end of the spectrum of an even broader category of Pervasive Developmental Disorders (PDD).
- Some types of autism that have been described include Typical Autism, Atypical Autism/PDD, Autistic Savants, Asperger's Syndrome, and autism associated with Kanner's Syndrome, fragile X, Rett and Down's syndromes.
- the overall prevalence of the broadest category of abnormal developmental progression is thought to occur in 1 in 300 children, 1 in 500 children will be born on the autistic spectrum and 1 in 1000 with severe autism.
- Autism has a clear genetic predisposition which is based on the fact that the probability of an identical twin having autism is around 50% as apposed to 0.5% in the general population. The probability of autism in Down's Syndrome is also 10%.
- developmental disorders are thought to be caused by impaired cognitive functions. While brain imaging studies have most often implicated the cerebellum in autism, abnormalities in many other brain areas have been reported, including limbic areas, thalamus, hypothalamus, the brain stem, the neocortex, and even the pineal gland. In accordance with the spectrum of symptoms and potential causes of autism, a variety of intervention treatments have emerged, including behavioral, sensory, sensory-motor integration, cognitive enhancing therapies, and various nutritional and pharmacological treatments. Aside from helping by acting on selective symptoms, the efficacy of pharmacological treatments is, in general, very poor. While many children with autism do improve to some extent with behavioral intervention programs, most autistics will be unable to live independently and more than half will never learn to speak correctly.
- autistic phenotype is highly heterogenous, common features are high level cognitive abnormalities in memory, perception and attention.
- Applicants have shown that the autistic brain is not impaired in many key cognitive abilities, but rather that the handicap arises from excessive brain functions and capabilities.
- behavioral experiments have revealed that memory processes are enhanced making it difficult for the autistic to uncouple prior associations leading to rigidity in social adaptation and communication.
- Perceptual processes are enhanced making the autistic overly sensitive to sensory stimulation and attention is enhanced, making autistics inflexible to shifting attention easily and fluidly in a rapidly changing sensory world.
- Electrophysiological experiments have also revealed a massive increase in the probability of synaptic connections between pyramidal neurons in different neocortical layers indicating that the local microcircuitry in the autistic neocortex is hyper-connected.
- the electrophysiological experiments also reveal an altered and greatly enhanced form of synaptic plasticity, which is thought to underlie memory formation as well as a large increase in the amount of NMDA-receptor triggered currents, which causes plasticity.
- Protein assays revealed an increase in the NMDA receptor levels in particular subunits NR2A and NR2B, indicating that there is a massive increase in currents that can be triggered by NMDA receptors in autism. Electrophysiological data also show a compensatory decrease in excitability of neurons.
- U.S. Patent 6,362,226 discloses a method of treating autism in a patient, said method comprising administering to the patient an effective amount of a glutamine level reducing agent, a glycine level reducing agent or combinations thereof.
- an NMDA receptor antagonist can also be administered to the patient in combination of a glutamine level reducing agent and/or glycine level reducing agent.
- U.S. Patent 4,994,467 relates to a method that is provided for treating autism and other pervasive developmental disorders in children by the administration of a therapeutically effective amount of an NMDA receptor antagonist.
- NMDA receptor antagonists by, for example, Ketamine is a commonly used aneasthetic and low doses of NMDA antagonism can cause dissociative disorders and psychoses.
- U.S . Patent Application N° 2004/0067978 Al discloses the use of mGluR antagonists, preferably selective for mGluR5 receptors, in the hippocampus, for the treatment and prevention of disorders, including Fragile X, autism, mental retardation, schizophrenia and Down's Syndrome.
- this disclosure is based on the finding that mGluR-5 receptor activation causes depression of synaptic connections in the neocortex and they have the goal of trying to increase synaptic plasticity and memory processes.
- Antagonizing mGlur-5 receptors is therefore a good potential treatment for autistic neocortex, and for a very different reason than proposed by U.S. Patent Application N° 2004/0067978 Al.
- the treatment would be required chronically from as early after birth as possible to retard the formation of circuits and prevent the hyperconnectivity and resulting symptoms.
- This object has been achieved by providing a method for treating and/or preventing a Pervasive Developmental Disorder in a subject in need thereof comprising the step of modulating the synaptic connectivity in the neocortex by administering a therapeutically effective amount of a composition capable of reducing memory, perception and/or attention by either blocking synaptic strengthening, enhancing synaptic weakening, reducing synapse formation, enhancing synaptic breakdown, decreasing network excitability, increasing the level of network inhibition, reducing the supply of dopamine to the neocortex, blocking calcium channels, reducing intracellular calcium levels, and/or blocking the somatostatin receptor 2.
- the present invention concerns a method for treating and/or preventing a Pervasive
- Developmental Disorder in a subject in need thereof comprising the step of modulating the synaptic connectivity in the neocortex by administering a therapeutically effective amount of a composition capable of reducing memory, perception and/or attention by either blocking synaptic strengthening, enhancing synaptic weakening, reducing synapse formation, enhancing synaptic breakdown, decreasing network excitability, increasing the level of network inhibition, reducing the supply of dopamine to the neocortex, blocking NMDA receptors, blocking calcium channels, reducing intracellular calcium levels, and/or blocking the somatostatin receptor 2.
- a further object of the present invention is to provide a kit for the treatment for a
- Pervasive Developmental Disorder comprising a therapeutically effective amount of a composition capable of reducing memory, perception and/or attention and instructions to use.
- Another object of the present invention is to provide a diagnostic kit.
- the kit includes antibody markers to perform immunohistochemical stainings to test for the alteration in specific proteins levels and gene expression changes found in the autistic brain.
- Figures 1 depict the Hyperconnectivity.
- Fig. 1 d shows the increased number of di-synaptic connections between thick tufted layer 5 PCs (via interneuron (M) between the two PCs) (P ⁇ 0.0001, Chi-square). Data show mean ⁇ s.e.m.
- Figures 2 depict the Hyper-reactive network.
- Fig. 2 a represents the MEA stimulation with 16 electrodes (50Hz Poisson train, 300 ms) in layer 5 thick tufted pyramidal neurons.
- Fig. 2 b shows the integral of responses to MEA stimulation in current-clamped PCs as a function of stimulation amplitude.
- Fig. 2 c represents the number of spikes elicited by the MEA stimulation as a function of the stimulation amplitude.
- Fig. 2 d represents the number of network events elicited by the stimulation as a function of stimulation amplitude.
- the upper traces represent the response of a whole-cell patched layer 5 pyramidal neuron, with an emphasis on what is measured for each graph.
- Fig. 2 a represents the MEA stimulation with 16 electrodes (50Hz Poisson train, 300 ms) in layer 5 thick tufted pyramidal neurons.
- Fig. 2 b shows the integral of responses to MEA stimulation in current-clamped PCs as a function
- FIG. 2 e shows the MEA stimulation with 16 electrodes (50Hz Poisson train, 300 ms) in layer 2/3 pyramidal neurons.
- the upper traces represent the responses of the whole-cell patched layer 2/3 pyramidal cells.
- the grey area is the charge measured for the dose response curves. Data show mean ⁇ s.e.m. (*, P ⁇ 0.05; **, P ⁇ 0.01).
- Figures 3 depict the Hypoexcitability of pyramidal cells.
- Figures 4 represent the Anatomy of layer 5 pyramidal cells.
- Fig. 4 a shows an example of Sholl analysis of a layer 5 thick tufted pyramidal cell.
- Fig. 4 d is a picture of layer 5 somatosensory cortex, as used for pyramidal cell density counting. Thick tufted pyramidal cells were recognized by their characteristic apical dendrite, soma shape and size. The density was calculated in a volume of 180 ⁇ m x 180 ⁇ m x 30 ⁇ m. Fig.
- Fig. 4 f is an Example of the reconstruction of a connected pair of layer 5 pyramidal cells in the VPA-treated rats.
- the green stars represent the putative synapses. Data show mean ⁇ s.e.m.
- Figures 5 depict the enhanced CarnKII, NR2A and NR2B protein expression levels. Examples of Western blot gels and mean values reported as percentage of control.
- Figures 6 represent the Enhanced NMDA mediated synaptic currents.
- Fig. 6 a shows the Experimental scheme and example of response in the postsynaptic cell before (total) and after blocking of AMPA receptors with NBQX (NMDA). The difference between the control and NMDA traces give the AMPA trace.
- Fig. 6 b shows the Peak currents of AMPA and NMDA responses.
- Data show mean ⁇ s.e.m. (*, P ⁇ 0.05; **, P ⁇ 0.01).
- Figures 7 depict the Enhanced postsynaptic plasticity.
- Fig. 7 a,b,c show the LTP with extracellular stimulation in layer 2/3 pyramidal neurons
- a Experimental scheme, pairing protocol and example of mean response in a patched cell, before and after pairing .
- b Example of response amplitude as a function of time.
- the grey line represents the timing of the pairing protocol
- c Mean of percentage increase in the amplitude of the response to extracellular stimulation after pairing.
- Fig. 7 a,b,c show the LTP with extracellular stimulation in layer 2/3 pyramidal neurons
- a Experimental scheme, pairing protocol and example of mean response in a patched cell, before and after pairing .
- b Example of response amplitude as a function of time.
- the grey line represents the timing of the pairing protocol
- c Mean of percentage increase in the amplitude of the response to extracellular stimulation after pairing.
- Figure 8 shows enhanced fear memories after 1, 34 and 69 days and shows reduced ability to extinguish fear memories after 3 days of de-conditioning .
- the present invention relates to a method for treating and/or preventing a Pervasive Developmental Disorder in a subject in need thereof comprising the step of modulating the synaptic connectivity in the neocortex by administering a therapeutically effective amount of a composition capable of reducing memory, perception and/or attention by either i) blocking synaptic strengthening, ii) enhancing synaptic weakening, iii) reducing synapse formation, iv) enhancing synaptic breakdown, v) decreasing network excitability, vi) increasing the level of network inhibition, vii) reducing supply of dopamine to the neocortex, viii) blocking the somatostatin receptor 2, wherein compositions i) to viii) are administered separately or concurrently in different combinations.
- PDD refers to a group of disorders characterized by delays in the development of socialization and communication skills. Parents may note symptoms as early as infancy, although the typical age of diagnoses is before 3 years of age. Symptoms may include problems with using and understanding language; difficulty relating to people, objects, and events; unusual play with toys and other objects; difficulty with changes in routine or familiar surroundings, and repetitive body movements or behavior patterns.
- the PDD to be treated are selected from the group comprising Fragile X, autism, mental retardation, schizophrenia and Down's Syndrome.
- the PDD is autism.
- autism comprises Typical Autism, Atypical Autism/PDD, Autistic Savants, Asperger's Syndrome, and autism associated with Kanner's Syndrome, fragile X, Rett and Down's syndromes.
- compositions of the invention are coadministered either by administering individual compositions or by administering a cocktail of said compositions.
- neurocortex refers to the evolutionary newest brain region that comprises almost 80% of the human brain. It is the upper mantel covering the paleo and archi cortices. It is the part of the brain the processes sensations, motor actions and high level cognitive functions such as perception, attention and memory.
- the term “subject” refers to any animal classified as a mammal including humans, domestic and farm animals, and zoo, sports or pet animals, such as dogs, horses, cats, cows, monkeys, etc.
- the mammal is a human.
- modulating include stimulation (e.g. increasing or upregulating a particular response or activity) and inhibition (e.g. decreasing or downregulating a particular response or activity).
- Synaptic connectivity refers to the connections formed between neurons to transmit information.
- a single synaptic connection is comprised of multiple synapses, typically 5-10.
- Synaptic plasticity refers to changes in the strength of synaptic connections. Long term synaptic plastic changes are also called either Long Term Potenatiation (LTP) or Long Term Depression (LTD) depending on the direction of the change.
- LTP Long Term Potenatiation
- LTD Long Term Depression
- administering refers to contact of a pharmaceutical, therapeutic, diagnostic agent or composition, to the subject, preferably a human.
- a “therapeutically effective amount” is an amount effective to ameliorate or prevent the symptoms, or prolong the survival of, the subject being treated. Determination of a therapeutically effective amount is well within the capabilities of those skilled in the art, especially in light of the detailed disclosure provided herein.
- An "agonist” is a molecule which activates a certain type of receptor.
- glutamate molecules act as agonists when they excite excitatory amino acid (EAA) receptors.
- an "antagonist” is a molecule which prevents or reduces the effects exerted by an agonist on a receptor.
- NMDA antagonists are drugs that can suppress excitatory activity of glutamate or glycine at NMDA receptors.
- a "blocker” refers to an antagonist which is a chemical compound that binds to a receptor or ion channel to prevent its function.
- agonist and antagonist drugs are generally thought to interact directly with receptors to achieve their effects, such effectivity may not result from direct interaction but may involve intermediate steps or compounds.
- the present invention is not limited to mechanisms acting directly on affected receptors involved or thought to be involved in autistic disorders. Rather, any effect of the drugs on receptors or more generally on metabolism or symptoms of the disorder is contemplated as part of the present invention.
- drug refers to chemical, peptidic or natural compounds which, when incorporated in the composition of the invention, or even alone, are capable of reducing memory, perception and/or attention by either blocking synaptic strengthening, enhancing synaptic weakening, reducing synapse formation, enhancing synaptic breakdown, increasing network excitability, decreasing the level of network inhibition, reducing supply of dopamine to the neocortex, blocking alpha 1 noradrenergic receptors, or blocking the somatostatin receptor 2.
- drugs of different origin and with different modes of action e.g. they can be agonists, antagonists, inhibitors, enhancers, blockers or down regulators.
- Applicants have completed a number of studies which allow a better understanding of the hyper connectivity associated with PDD. Applicants have shown that hyperconnectivity is not due to excessive growth of axons or dendrites or boutons or synapses. Instead a novel form of target dominance seems to be activated.
- the Target Dominance (TD) mechanism determines the number of target neurons contacted by a neuron.
- regulatory mechanisms such as those from the prefrontal cortex that control executive functions.
- the predicted consequence is that the local microcircuits of the neocortex become overly sensitive, hyper-reactive, autonomously active and difficult to control.
- the cognitive level this is predicted to translate into severe abnormalities in perception, attention and memory.
- the perceptual abnormality is proposed to be due to oversensitivity and over- reactivity of the local circuits.
- the attention abnormality is proposed to be due to the autonomous local circuits which can not be controlled by attention mechanisms.
- the memory abnormality is proposed to be due excessive storage of memories in the hyper-connected networks causing behavioral rigidity and inflexibility to new environments.
- Applicants have also shown which key molecules are involved in the TD mechanism. Additionally, they have shown that it is possible to change the target profile of neurons, i.e. the set of neurons that each neuron targets. Experience and intense excitation of the circuit (equivalent to an intense experience) can enhance TD resulting in hyperconnectivity. Accordingly, Applicant's can therefore induce hyper-connectivity in the normal brain with intense activation.
- the therapeutically effective amount of a composition of the present invention capable of reducing memory, perception and/or attention by blocking synaptic strengthening comprises a drug selected from the group comprising a muscarinic receptor antagonist, acetylcholin esterase enhancer, N-methyl-D-aspartate (NMDA) receptor antagonist, second messenger blocker, calcium channel blocker, group IE metabotropic glutamatergic receptor agonist (group IH mGluR), intracellular calcium buffer molecule and/or a combination thereof.
- a muscarinic receptor antagonists aimed at reducing the supply of acetylcholine to the neocortex, comprise, but are not limited to:
- Muscarinic antagonists having a selectivity for muscarinic receptors Mi > ML 2 ; e.g. Nitrocaramiphen hydrochloride (2-Diethylaminoethyl l-(4- nitrophenyl)cyclopentanecarboxylate hydrochloride),
- Muscarinic M ⁇ antagonists e.g. 4-DAMP (l l> l-Dimethyl-4-diphenylacetoxypiperidinium iodide),
- Antagonist-receptor complex stabilisers e.g. W-84 dibromide (Hexamethylene-bis-[dimethyl-(3- phthalimido ⁇ ropyl)ammonium]dibromide),
- Muscarinic antagonist e.g. Ipratropium bromide (e«Jo,j>' «X ⁇ )-3-(3-Hydroxy-l-oxo-2-phenylpropoxy)-8-methyl-8- (l-methylethyl)-8-azoniabicyclo[3.2.1]octane bromide),
- M 4 selective muscarinic receptor antagonist e.g. Tropicamide (jV-Ethyl-3-hydroxy-2-phenyl-N-(pyridinylmethyl)propanamide) 5
- Mj_ muscarinic antagonist e.g. Pirenzepine dihydrochloride (5,ll-Dihydro-l l-[(4-methyl-l-piperazinyl)acetyl]-6/i- pyrido[2,3-b][l,4]benzodiazepin-6-one dihydrochloride),
- AF-DX 116 (l l-[[2-[(Diethylamino)methyl]-l-pi ⁇ eridinyl]acetyl]-5,ll-dihydro-6H " - pyrido[2,3-b][l,4]benzodiazepin-6-one) or Otenzepad,
- Potent MTZM 4 antagonists e.g. AF-DX 384 (ll-ttl-tCDiethylamino ⁇ nethy ⁇ -l-piperidinyllacetylJ-SJl-dihydro- ⁇ H- pyrido[2,3-b] [ 1 ,4]benzodiazepin-6-one) or Otenzepad,
- Non-selective muscarinic antagonists e.g. Scopolamine hydrobromide (( ⁇ ,S)- ⁇ -( ⁇ ydroxymethyl)benzeneacetic acid
- M?-selective antagonists e.g. (5)-(+)-Dimetbindene maleate (iV,iV-Dimethyl-3-[(15)-l-(2-pyridinyl)ethyl]-lH-indene-2- ethanamine maleate),
- Selective M 4 antagonists e.g. PD 102807 (3 5 6a,ll,14-Tetrahydro-9-methoxy-2-methyl-(12H)-isoquino[l,2- 6]pyrrolo[3,2 : /][l,3]benzoxazine-l-carboxylic acid, ethyl ester),
- ICso values are 91, 6559, 3441, 950 and 7412 nMfor human M 4 , Mj, M 2 , M 3 , and Ms receptors respectively
- Muscarinic receptor inhibitors such as Type 1 and Type 2 inhibitors.
- Modulators of cholinergic function usually acetylcholine esterase enhancers: such as Cholinesterase inhibitor (e.g. Ambenonium dichloride, Galanthamine hydrobromide, Tacrine hydrochloride), ACh release Stimulators (e.g. MR 16728 hydrochloride, Cisapride), Cholinesterase inhibitor (e.g. Physostigmine hemisulfate), ACh transport inhibitor (e.g. ( ⁇ )- Vesamicol hydrochloride), Presynaptic cholinergic modulator (e.g. PG-9 maleate), Presynaptic cholinergic modulator (e.g. SM-21 maleate).
- Exemplary mGluR Group HI mGluR 4, 6, 7 and 8 agonists comprise, but are not limited to:
- L- AP4 L(+)-2-amino-4-phos ⁇ honobutyric acid (L- AP4), (S)-3,4-dicarboxyphenylglycine (DCPG), selective mGluR8 subunit (a) agonist,
- NMDA receptor does not determine TD, but determines the strength of existing synapses. It is well known that NMDA receptors control the strength of synapses, but it was not known that target selection can be made without NMDA. The involvement of NMDA receptors in plasticity of existing synapses is therefore likely to be important in the memory processes after neurons are contacted and in the case of Autism after the TD mechanism has been activated.
- NMDA receptor antagonists comprise, but are not limited to:
- NMDA Site antagonists such as:
- DL-AP5 (DL-2-Amino-5- ⁇ hosphonopentanoic acid), D-AP5 (D-(-)-2-Amino-5-phosphonopentanoic acid), L-AP5 (L-(+)-2-Amino-5-phosphonopentanoic acid), D-AP7 (D-(-)-2-Amino-7-phosphonoheptanoic acid),
- SDZ 220-581 (( ⁇ - ⁇ -Amino ⁇ '-chloro-S-CphosphonomethyOt ⁇ r-biphenyy-S-propanoic acid),
- SDZ 220-040 ((5)- ⁇ -Amino-2',4'-dichloro-4-hydroxy-5-(phos ⁇ honomethyl)-[l,r-biphenyl]- 3 -propanoic acid),
- Glycine Site Antagonists such as: CNQX (6-Cyano-7-nitroquinoxalme-2,3-dione),
- ACBC l-Aminocyclobutane-l-carboxylic acid
- L-701,324 (7-Chloro-4-hydroxy-3-(3- ⁇ henoxy) ⁇ henyl-2(lH)-quinolinone), CGP 78608 hydrochloride ([(lS)-l-[[(7-Bromo-l,2,3,4-tetrahydro-2,3-dioxo-5- quinoxalinyl)methyl]amino]ethyl]phosphonic acid hydrochloride).
- Ion Channel Antagonists such as: ( ⁇ )-l-(l,2-Diphenylethyl)piperidme maleate,
- Memantine hydrochloride 3,5-Dimethyl-tricyclo[33 J J3,7]decan-l-amine hydrochloride
- Dizocilpine (+)-MK 801 maleate)
- (5S, 10R)-(+)-5-Methyl- 10, 1 l-dihydro-5H-dibenzo[a,d]cyclohepten-5, 10-imine maleate
- Loperamide hydrochloride (4-(4-Chloro ⁇ henyl)-4-hydroxy-N,N-dimethyl-a,a-diphenyl-l- piperidinebutanamide hydrochloride),
- a Ca 2+ channel blocker at low micromolar concentrations it blocks broad spectrum neuronal HVA Ca 2+ channels and at higher concentrations it reduces Ca 2+ flux through NMDA receptor operated channels Remacemide hydrochloride (2- Amino-N-(1 -methyl- l,2-diphenylethyl)acetamide hydrochloride),
- IEM 1460 shows selectivity between subtypes, blocking GluR2 subunit-lacking (Ca 2+ -permeable) cerebellar receptors more potently than GluR2-containing hippocampal receptors (IC so values are 2.6 and 1102 mM respectively.
- NMDA receptor antagonist IC 50 — 5 mM
- Polyamine Site Antagonists such as:
- N-(4-Hydroxyphenylacetyl)spermine N-(N-(4-Hydroxyphenylacetyl)-3-ammo ⁇ ropyl)-(N'-3- aminopropyl)- 1 ,4-butanediamine,
- N-(4-Hydroxyphenylpro ⁇ anoyl) spermine trihydrochloride N-(N- (4Hydroxyphenylpropanoyl)-3-aminopropyl)-(N'-3-ammopropyl)-l,4-butanediamine trihydrochloride )
- Ifenprodil hemitartrate (2-(4-Benzylpiperidino)-l-(4-hydroxyphenyl)-l-propanol hemitartrate),
- Non-competitive NR2B-selective NMDA antagonist also s ligand and Ca 2+ channel blocker.
- Other NMDA selective Antagonists such as:
- Bilobalide a constituent of Ginkgo Biloba, Lipocortin-1, Cerebral Fluid Zinc level elevators
- the NMDA antagonists are selective for NMDA receptor subunits NR2A and/or NR2B.
- mGluRs while intensely activating the circuit, causes synapses to get stronger indicating that these receptors normally serve to keep synapses from becoming to too strong. Activating these receptors therefore prevent the hyper-plasticity associated with the hyper-connectivity.
- Group 3 mGluRs act by inhibiting the cyclic AMP pathway, which normally activates the Protein Kinase A (PKA) enzyme. PKA phosphorylation of the 2B NMDA receptor subunit is excessive and thus activating the group 3 receptor prevents this phosphorylation and reduces the NMDA mediated current.
- PKA Protein Kinase A
- second messengers are molecules that relay signals received at receptors on the cell surface such as the arrival of protein hormones, growth factors, etc. to target molecules in the cytosol and/or nucleus.
- cyclic nucleotides ⁇ e.g., cAMP and cGMP
- IP 3 inositol trisphosphate
- DAG diacylglycerol
- Ca 2+ calcium ions
- the second messenger of the present invention is the Ca 2+ ion.
- Calcium ions are important intracellular messengers since they are probably the most widely used intracellular messengers. The applicants have evidence for an increase in current triggered by NMDA receptors.
- Some of this current may be a high voltage activated channel that does not inactivate.
- Such channels are typically from the L and N type calcium channel classes.
- a rise in the concentration of Ca 2+ in the cytosol triggers many types of events such as e.g. release of neurotransmitters at synapses (and essential for the long-term synaptic changes that produce Long-Term Potentiation (LTP) and Long-Term Depression (LTD).
- LTP Long-Term Potentiation
- LTD Long-Term Depression
- an intracellular Ca 2+ levels blocker or reducer such as Acetoxymethyl (AM) or Acetate Esther versions of buffers, intracellular calcium release blockers, gene therapeutic agents that induce enhanced expression of calcium buffers, Signal Transduction Agents (e.g.
- CaM kinase II inhibitors CaM kinase IV inhibitors, Myosin light chain kinase inhibitors
- Calcium Signalling Agents e.g. Calmodulin antagonists
- compositions capable of reducing memory, perception and/or attention by reducing intracellular calcium changes comprising a drug selected from the groups comprising the NMDA receptor antagonists, the non-inactivating Calcium channels antagonists, the blockers of intracellular calcium release, a blocker of the metabotropic receptor class of neurotransmitters that are linked to the intracellular release of calcium such as, for example, the metabotropic glutamate receptors from group I, and/or a combination thereof.
- the present invention also envisioned a composition capable of reducing memory, perception and/or attention by preventing release of calcium from intracellular stores by blocking the activation of alpha 1 adrenergic receptors, said composition comprises a drug selected from the group comprising a noradrenergic receptor antagonist, a noradrenergic uptake enhancer, and/or a combination thereof.
- Exemplary calcium channel blockers comprise, but are not limited to: Ca 2+ channel blocker fL-type)
- Nimodipine (l,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2- methyloxyethyl 1-methylethyl ester),
- Nitrendipine (l,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5- ⁇ yridine dicarboxylic acid ethyl methyl ester), Verapamil hydrochloride ( ⁇ -[3-[[2-(3,4-Dimethoxyphenyl)ethyl]methylamino]propyl]-3,4- dimethoxy- ⁇ -(l-methylethyl)benzeneacetonitrile hydrochloride),
- Nifedipine (l,4-Dihydro-2,6-dimethyl-4-(2-nitro ⁇ henyl)-3,5- ⁇ yridinedicarboxylic acid dimethyl ester),
- L-T ype calcium channel blockers such as those from the dihydropyridine, phenylalkylamines and benzothiazepine chemical classes.
- Felodipine (PlendilTM, LexxelTM),
- Nicardipine (CardeneTM), Nifedipine (AdalatTM, ProcardiaTM),
- Nimodipine (Nimotop TM)
- Nisoldipine (SularTM), Verapamil (IsoptinTM), Diltiazem (Angizem, Altiazem), Bepridil (VascorTM).
- the therapeutically effective amount of a composition of the present invention capable of reducing memory, perception and/or attention by enhancing synaptic weakening includes also a drug selected from the group comprising a metabotropic glutamatergic receptor (mGluR) antagonist, a CREB gene down regulator, a CREB phosphorylation blocker and/or a combination thereof.
- mGluR metabotropic glutamatergic receptor
- mGluR5 triggers a signaling pathway called the Inositol Phosphate Pathway. This pathway is a controlled by Ca2+ influx into neurons which occurs during electrical activity and attenuating this pathway is therefore also a potential target for treating autism.
- the metabotropic glutamatergic receptor (mGluR) antagonists are mGluR Group I antagonists.
- mGluR Group I antagonists will selectively target the neocortex, most preferably by differential affinities of the antagonists.
- mGluR5 a member of the niGluR Group I, triggers a signaling pathway called the Inositol Phosphate Pathway. This pathway is a controlled by Ca2+ influx into neurons which occurs during electrical activity and attenuating this pathway is therefore also useful for reducing memory, perception and/or attention by enhancing synaptic weakening.
- Exemplary mGluR Group I antagonists comprise, but are not limited to: DL-AP3 (DL-2-Amino-3-phosphonopropionic acid),
- ADDA ((RS)-l-Aminoindan-l,5-dicarboxylic acid
- SIB 1757 (6-Methyl-2-( ⁇ henylazo)-3- ⁇ yridinol), 0.4 mM at HmGIu 5
- Kb values are 140 and 110 mM at mGlu] a and mGlu 5a receptors respectively.
- K b values are 30 and 61 mMat mGluj a and mGlu 5a receptors respectively MATIDA ( ⁇ -Amino-5-carboxy-3-methyl-2-thioplieneacetic acid 3-),
- ACDPP hydrochloride (3-Amino-6-chloro-5-dimethylamino-N-2- pyridinylpyrazinecarboxamide hydrochloride),
- CREB Cyclic-AMP Response Element Binding proteins in neurons are involved in the formation of long-term memories and that they are necessary for the late stage of long term potentiation (LTP)
- the present invention also envisioned either to down regulate the CREB gene or to block the phosphorylation CREB protein.
- Down regulating the CREB gene could, for example, occur by using gene regulating mechanisms that limits the transcript level by either suppressing transcription of CREB gene (transcriptional gene silencing), by activating a sequence-specific RNA degradation process (posttranscriptional gene silencing i.e. PTGS/RNA interference), by activating the CREM gene or by the phosphorylation of CREB such as for example on residue 142 or 123.
- the therapeutically effective amount of a composition of the present invention capable of reducing memory, perception and/or attention by reducing synapse formation comprises a drug selected from the group comprising a NCAM expression inhibitor, a synaptophysin expression inhibitor, a cell-to-cell protein expression inhibitor, a receptor recycling inhibitor, and/or a combination thereof.
- Cell-to-cell proteins can be selected from the group comprising ephrins, cadherins and cathenins.
- compositions capable of reducing memory, perception and/or attention by enhancing synaptic breakdown that comprises a drug selected from the group comprising a NOGO expression enhancer, a blocker that prevents the binding of polysialic acid (PSA) to NCAMs such as endoneurarainidase-N (endo-N), and/or a combination thereof.
- a drug selected from the group comprising a NOGO expression enhancer, a blocker that prevents the binding of polysialic acid (PSA) to NCAMs such as endoneurarainidase-N (endo-N), and/or a combination thereof.
- endoneurarainidase-N endoneurarainidase-N
- compositions capable of reducing memory, perception and/or attention by reducing network excitability that comprises a drug that inhibits potassium or calcium channels.
- the neurons in autistic animals display a damped down excitability. This is due to the over expression of a variety of potassium channels.
- said drag will act by blocking the SK2 calcium sensitive potassium channels, or by blocking the BK Ca sensitive potassium channel, or by blocking voltage-gated postassium channels such as the ion channel encoded by the Kv 3.2 and/or the Kv4 beta gene gene, or by blocking L, N, P and/or Q -type calcium channels.
- a therapeutically effective amount of a composition capable of reducing memory, perception and/or attention by increasing the level of network inhibition comprises a drag selected from the group comprising a cannabinoid receptor 1 inhibitor, a gamrna-amino butyric acid A (GABA-A) agonist or attenuator, a gamma-amino butyric acid B (GABA-B) agonist or attenuator and/or a combination thereof.
- GABA-A gamrna-amino butyric acid A
- GABA-B gamma-amino butyric acid B
- GABA-B inhibitor is a GABA-B agonist, then it is selected from the group comprising, but not limited to:
- CBl 3-Aminopropyl(methyl)phosphinic acid
- Gene expression analysis indicates that there is an increased expression of the cannabinoid receptor 1, suggesting that autistics are able to "self-administer" anxiety reducing behavior. Inhibition of the cannabinoid receptor 1 will therefore encourage external reward seeking behavior.
- Also encompassed in the present invention is a therapeutically effective amount of a composition capable of reducing memory, perception and/or attention by reducing the supply of dopamine to the neocortex that comprises a drug selected from the group comprising a dopamine receptor inhibitor, a dopamine uptake enhancer, and/or a combination thereof.
- a composition capable of reducing memory, perception and/or attention by reducing the supply of dopamine to the neocortex that comprises a drug selected from the group comprising a dopamine receptor inhibitor, a dopamine uptake enhancer, and/or a combination thereof.
- somatostatin receptor 2 by Gene expression analysis. This receptor is activated by the release of the neuropeptide somatostatin from a special type of inhibitory neuron called a Martinotti cell.
- the Martinotti cell is crucial for maintaining electrical balance in the neocortex and imbalance could also account for the high tendency towards seizures and epilepsy in autism.
- An increase in the expression of the receptor indicates that these interneurons can exert a stronger inhibitory effect, which appears to be a compensatory effect to prevent hyper-excitability. Blocking this receptor in combination could force the hyper-connectivity in reverse.
- compositions capable of reducing memory, perception and/or attention by blocking the somatostatin receptor 2 that comprises a drug selected from the group comprising neuropeptide receptor blockers, somatostatin synthesis blockers, and/or a combination thereof.
- the composition may contain one or more pharmaceutically acceptable carriers, such as excipients, carriers and/or auxiliaries which facilitates processing of the active compounds into preparation which can be used pharmaceutically.
- the composition may contain, for example, 0.1 to 99.5%, more preferably 0.5 to 90%) of the drug.
- Acceptable carriers, excipients, or stabilizers are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl orbenzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine,
- administration of the composition maybe systemic and/or topical and/or via the nasal cavity.
- administration of such a composition may be various parenteral routes such as subcutaneous, intravenous, intradermal, intramuscular, intraperitoneal, intranasal, transdermal, buccal routes or via an implanted device, and may also be delivered by peristaltic means.
- composition comprising a drug, as described herein, as an active agent may also be incorporated or impregnated into a bioabsorbable matrix, with the matrix being administered in the form of a suspension of matrix, a gel or a solid support.
- the matrix may be comprised of a biopolymer.
- sustained-release preparations may be prepared. Suitable examples of sustained- release preparations include semi permeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g. films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No.
- copolymers of L-glutamic acid and [gamma] ethyl-L-glutamate non- degradable ethylene-vinyl acetate
- degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT(TM) (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid.
- the formulations to be used for in vivo administration must be sterile. This is readily accomplished for example by filtration through sterile filtration membranes.
- the suitable dosage of the composition of the present invention will be dependent upon the age, sex, health, and weight of the recipient, kind of concurrent treatment, if any and the nature of the effect desired.
- the appropriate dosage form will depend on the disease, the drug, and the mode of administration; possibilities include tablets, capsules, lozenges, dental pastes, suppositories, inhalants, nasal inhalers, solutions, ointments and parenteral depots.
- the selected dosage level will depend upon a variety of factors including the activity of the particular compound, or combination of compound, of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular reuptake inhibitors employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
- a physician having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required.
- the physician could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
- a suitable daily dose of a composition of the invention will be that amount of the composition which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. Generally, intravenous, intracerebroventricular and subcutaneous doses of the composition of this invention for a patient will range from about 0.0001 to about 100 mg per kilogram of body weight per day. If desired, the effective daily dose of the composition may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.
- composition of the invention are associated with an antidepressant drug such as selective serotonin-reuptake inhibitors (SSRIs), an anticonvulsive drug, or an antipsychotic drug, or and combinations thereof, the dosage level may vary accordingly.
- an antidepressant drug such as selective serotonin-reuptake inhibitors (SSRIs), an anticonvulsive drug, or an antipsychotic drug, or and combinations thereof
- SSRIs selective serotonin-reuptake inhibitors
- an anticonvulsive drug an anticonvulsive drug
- an antipsychotic drug or and combinations thereof
- the dosage level may vary accordingly.
- the described method not only applies to autistic children or autistic adults but also to pregnant non-autistic women in order to prevent the appearance of autistic conditions in the fetus, hi such a case, the therapeutically effective amount of a composition capable of reducing memory, perception and/or attention according to the present invention will be administered as soon as a diagnosis is possible. It is not currently possible to diagnose an autistic fetus, but a gene expression screen of amitotic fluid may reveal the changes found in autism. Treatment must start as early as possible to prevent the formation and consolidation of this disorder during development.
- treatment will start within the first three years of the children, but because plasticity of the circuitry continues well beyond adulthood, the prescribed treatment regime can be administered effectively at any age.
- composition of the invention in the preparation of a medicament for treating and/or preventing a Pervasive Developmental Disorder.
- kits for treating and/or preventing a Pervasive Developmental Disorder in a subject in need thereof comprising a therapeutically effective amount of a composition of the present invention capable of reducing memory, perception and/or, optionally with reagents and/or instructions for use.
- the kit of the present invention may further comprise a separate pharmaceutical dosage form comprising an antidepressant drug such as selective serotoriin-reuptake inhibitors (SSRIs), an anticonvulsive drug, or an antipsychotic drug, and combinations thereof.
- an antidepressant drug such as selective serotoriin-reuptake inhibitors (SSRIs), an anticonvulsive drug, or an antipsychotic drug, and combinations thereof.
- the Kit comprises a container and a label or package insert on or associated with the container.
- Suitable containers include, for example, bottles, vials, syringes, etc.
- the containers may be formed from a variety of materials such as glass or plastic.
- the container holds a composition which is effective for treating the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
- At least one active agent is a composition of the present invention.
- the Kit may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.
- a pharmaceutically-acceptable buffer such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution.
- Wistar Han rats (Charles River Laboratories, L'Arbresle, France) were mated, with pregnancy determined by the presence of a vaginal plug on embryonic day 1 (El).
- the sodium salt of valproic acid NaVPA, Sigma
- the dosing volume was 3.3 ml/kg, the dosage was adjusted according to the body weight of the animal on the day of injection.
- Treated rats received a single ip injection of 500 mg/kg NaVPA on gestation day GD 12.5, control rats were untreated [I]. Delivery of this dose to rats during embryogeneis has been shown to result in maximum levels of total valproic acid in maternal plasma in less than 1 hour, with a mean plasma elimination half life of 2.3 h [2].
- Offspring (PN12 to PN16) were rapidly decapitated and sagittal neocortical slices (300 ⁇ m) were sectioned on a vibratome (HR2, Sigmann Elektronik) filled with iced extracellular solution. Optimal slices, running parallel to the apical dendrites of pyramidal cells, were selected for recording. Slices were incubated for 30 minutes at 35 0 C and then at room temperature until transferred to the recording chamber (room temperature or 34 0 C).
- the extracellular solution contained (niM): 125 NaCl, 2.5 KCl 5 25 glucose, 25 NaHCO 3 , 1.25 NaH 2 PO 4 , 2 CaCl 2 and 1 MgCl 2 .
- Neurones in somatosensory cortex were identified using IR-DIC microscopy, with an upright microscope (Olympus Bx51Wl, fitted with a 60x/0.90 W objective, Olympus, Switzerland). Recorded neurons were selected up to 70 ⁇ m below the surface of the slice.
- neurones were submitted to a series of somatic current injection designed to capture their key active and passive electrical properties. Recordings were sampled at intervals of 10-400 ⁇ s using Igor (Wavemetrics, Lake Oswego, OR, USA), digitized by an ITC- 18 interface (Instrutech, Great neck, NY, USA) and stored for off-line analysis. The results were calculated as a mean of 89 cells from control rats and 100 cells from NaVPA treated rats. Connectivity: Synaptic direct connections were examined by eliciting short trains (8 pulses) of precisely timed action potentials (APs) at different frequencies (20 to 70 Hz) followed by a recovery test response 500 ms later.
- APs precisely timed action potentials
- the average synaptic response to this stimulation protocol allows the extraction of the basic parameters of the synaptic connection with a model of dynamic synaptic transmission (Ase, the absolute strength of the connection; U, equivalent to average P; d, the time constant to recover from depression) [3]
- the number of analyzed connections was 41 for control slices, 33 for treated slices.
- PCs thick tufted layer V pyramidal cells
- AP action potential
- connection was, five minutes after a testing period (same protocol as described above ), stimulated with a pairing protocol consisting of Poisson train stimulation of high frequency (50Hz) to the postsynaptic cell and of low frequency (5Hz) to the presynaptic cell, for 30 seconds.
- MEA stimulation Multi-site extracellular stimulations were performed using a multi-electrode array (MEA) made of 60 3D Pt electrodes (Ayanda Biosystems, EPFL, Switzerland), on top of which acute brain slices were glued with a solution of nitrocellulose (0.14 mg/ml in ethanol). The responses of these stimulations were recorded in whole-cell patched layer 2/3 pyramidal cells. For the study of cell response with minimal network stimulation, 8 different MEA electrodes were stimulated non- simultaneously (single pulse of 0.5 to 1. IV) and current were recorded in V-clamped cells (holding voltage between -80 and -4OmV). Total synaptic, excitatory and inhibitory conductances could then be calculated according to the method described in [4].
- N-Methyl-D-aspartate receptors were blocked using 20 ⁇ M D-2-amino-5- phosphonopentanoic acid (D-APV, Sigma).
- L-amino-3-hydroxy-5-methyl-4- isoxazolepropionate receptors were blocked using 10 ⁇ M 6-cyano-7- nitroquinoxaline-2,3-dione (CNQX disodium salt, Sigma), ⁇ -aminobutyric acid A receptors (GABA A RS) were blocked using 20 ⁇ M bicuculline (Sigma).
- GABA B RS were blocked using 100 ⁇ M CPG-35348 (Tocris).
- Lidocaine n-ethylbromide quaternary salt QX-314, 5 ⁇ M, Sigma
- 3-D neurone models were reconstructed from five control and five treated stained cells using Neurolucida system (MicroBrightField Inc., USA) and a bright-field microscope (Olympus).
- the startle apparatus (Columbus Instruments, Ohio) consisted of aplastic, transparent cage, equipped with a movable platform floor attached to a sensor, which recorded vertical movements of the floor. A loudspeaker was suspended above the cage, and it was placed in a soundproof box. A transient force resulting from up-and-down movements of the floor, evoked by a startle reaction to acoustic stimuli, was recorded by PC using a recording window of 200 ms measured from the onset of the acoustic stimulus. The amplitude of a startle response was defined as a difference between the average force detected within a recording window and the force measured immediately before the stimulus onset. The threshold was set at 20 g and allowed for correct evaluation of the maximum response in all the animals tested.
- the experiment started with an adaptation period during which the animals were placed in experimental cages for 5 min and exposed to a 70 dB background white noise. Following habituation, baseline startle responses were recorded by confronting the rats with 5 tone pulses (15 dB, with a random intertrial interval of 10-30 sec). Immediately afterwards a series of prepulse-pulse stimulation was initiated consisting of 12 pulse alone trials, and 4 prepulse- pulse combinations, each made up by 6 trials. The combinations consisted of either a 78 or 86 dB prepulse tone preceding the main pulse by either 30 or 120 ms. Each trial was separated by a random intertrial interval of 10 to 30 sec. The trial order was random. The experiment concluded with a series of 5 pulses alone, the same as during baseline recordings.
- Prepulse inhibition was calculated as the percentage of inhibition of the startle amplitude evoked by pulse alone: ((pulse-prepulse)/pulse) x 100.
- rats were re-conditioned to the tone (0.5 mA, 1 sec) in order to re-establish the fear memory and underwent a two-day extinction procedure consisting of a 30 min protocol per day, in which 20 sec tone intervals alternated with 40 sec no-tone intervals. Over the two days, rats were exposed to 60 tone stimulations in total. One day and one month after extinction training animals were re-tested for their tone memory using the same protocol as in the previous tone tests.
- each rat was scored blindly as either freezing or active. Freezing was defined as behavioural immobility except for movement needed for respiration.
- Training and testing took place in a black, circular water tank (170 cm in diameter, 50 cm high, custom-made in the house) surrounded by grey curtains containing several spatial cues (e.g. plastic flowers, geometrical patterns, poster or clothes attached to the curtains and walls).
- the water temperature was 25° C +/- 1 ° C.
- a 12 cm in diameter escape platform was placed with the top surface 1.5 - 2.5 cm below the water level at one of four positions in the pool.
- Each trial was initiated by placing the animal in one of four randomly chosen locations near the wall of the tank. Animals were allowed to search for the hidden platform for a maximum of 90 sec. If an animal reached the platform before the maximum time, the trial was stopped. In case the animal did not find the platform during this time, it was guided by the experimenter towards it and in both cases it was left on the platform for further 30 sec.
- Each learning day consisted of four consecutive learning trials, with 30 sec intertrial intervals. In total a session would last maximally 8 min.
- Training consisted of a total of four learning sessions. One day and approximately three weeks later, spatial memory was tested in probe trials by removing the platform from the pool and placing the animal for 90 sec into the pool. After the second probe trial animals received two more learning sessions on consecutive days in order to re-establish a strong spatial memory. The following day, the platform was changed to the opposite position and rats underwent a final reversal learning session, the protocol being the same as above.
- Wistar rats 13-16 days old were rapidly decapitated and neocortical slices (sagittal; 300 mm thick) were sectioned on a vibratome (DSK, Microslicer, Japan) filled with iced extracellular (mM): 125 NaCl, 2.5 KCl, 25 glucose, 25 NaHCO 3 , 1.25 NaH 2 PO 4 , 2 CaCl 2 , and 1 MgCl 2 .
- Neurones were identified using IR-DIC microscopy as previously described. Somatic whole-cell recordings of layer 5 pyramidal cells (pipette resistance-3 M ⁇ ) were employed for harvesting their cytoplasmic contents.
- Pipettes were filled with RNase free intracellular solution, containing (mM) 100 potassium gluconate, 20 KCl, 4 ATP-Mg, 10 phosphocreatine, 0.3 GTP and 10 Hepes (pH 7.3, 310 mOsmol, adjusted with sucrose).
- the intracellular solution was prepared under RNAse free conditions: water was autoclaved; glassware and pH meter were cleaned with NaOH (10N) and chemicals were opened from the first time using gloves and RNAse free tools. After preparation, the intracellular solution was tested for RNAse contamination. Right after whole cell configuration, cell cytoplasm was aspirated into the recording pipette under visual control by applying gentle negative pressure.
- RNA messenger was reverse transcribed using an oligo-dT and linearly amplified using a two round amplification kit (Epicenter) The quality of the amplified RNA was controlled on a Nano LabCbip (Agilent Technologies) and samples with high quality aRNA were either a) labeled and hybridize on oligonucleotide microarrays (Agilent and/or Affymetrix); or b) tested for the quantitative expression of selected genes using real time PCR (Applied Biosystems).
- Wistar rats 14 days old were rapidly decapitated and their brains (entire or one hemisphere) were immediately frozen in 2-methylbutane-dry ice mix, and stored at - 80 0 C.
- Coronal 8-12 um sections were cut on a cryostat and thaw mounted on PEN-membrane coated or non-coated glass slides. Sections were stained with brief Nissl stain for neuronal identification: 70% ethanol 1 min, water 5 dips, 1% cresyl violet 20 s, water 5 dips, processing through graded ethanols 70/95/100% (30 s each) and xylene 5 min. Neurons were captured using two LCM systems: AutoPix LCM system (Arcturus) and PALM MicroLaser System (P.A.L.M. Microlaser Technologies): Laser capture microdisection using the AutoPix LCM system (Arcturus).
- layer 5 pyramidal cells somatosensory cortex and prefrontal cortex
- AutoPix LCM system Arcturus
- the captured cells were collected onto CapSureTM HS caps covered with a thermoplastic film.
- the harvested cells were solubilized from the film in extraction buffer provided in the Arcturus Pico PureTM RNA isolation kit for 30 min at 40 0 C and stored at -80 0 C.
- layer 5 pyramidal cells somatosensory cortex and prefrontal cortex
- PALM MicroLaser System P.A.L.M. Microlaser Technologies
- the captured cells were collected onto PALM AdhesiveCaps.
- the harvested cells were solubilized in extraction buffer provided in the RNeasy Micro Kit, Qiagen and stored at -8O 0 C.
- RNA 600 Nano LabChip (Agilent Technologies).
- the captured material (pooled of single neurons) was DNAse I treated and the RNA was purified using silica-gel- membrane columns (Pico PureTM RNA isolation kit, Arcturus or RNeasy Micro Kit, Qiagen)
- silica-gel- membrane columns Pico PureTM RNA isolation kit, Arcturus or RNeasy Micro Kit, Qiagen
- RNA quality of the amplified RNA was controlled on a Nano LabChip (Agilent Technologies) and samples with high quality aRNA were either a) labeled and hybridize on oligonucleotide microarrays (Agilent and/or Affyrnetrix); or b) tested for the quantitative expression of selected genes using real time PCR (Applied Biosystems).
- Oligonucleotide microarrays (Agilent and Asymetrix) were analyzed (probe level data preprocessing, quality checks, normalization, and visualization) using the RACE (Remote Analysis Computation for gene Expression data suite), a collection of web tools designed to assist with the analysis of DNA microarray data and results.
- RACE Remote Analysis Computation for gene Expression data suite
- Rat brains were homogenized in 8 volumes of cold homogenization buffer A (0.32M sucrose, 1OmM HEPES/KOH, and the following protease inhibitors 0.3mM PMSF, 0.7 ⁇ g/ml Pepstatin, 2 ⁇ g/ml Aprotinin, 2 ⁇ g/ml Leupeptin) using a motor driven glass-teflon homogenizer.
- the homogenate was spun at 450Og in a Beckman centrifuge to remove the pelleted nuclear fraction, the supernatant was spun at lOOOOOg for 40min. in a Beckman ultracentrifuge.
- the pellet was resuspended in buffer B (20 niM HEPES/KOH pH7.4, 2 mM EDTA, 2 mM EGTA, 0.1 mM DTT) containing 0.1 M KCl, 0.3mM PMSF, 0.7 ⁇ g/ml
- Pepstatin 2 ⁇ g/ml Aprotinin, 2 ⁇ g/ml Leupeptin.
- the suspension was rehomogenized using a glass-teflon homogenizer and spun at lOOOOOg for 40min.
- Membrane pellets were lysed in buffer B (20 mM HEPES/KOH pH7.4, 2 mM EDTA, 2 mM EGTA, 0.1 mM DTT) containing 0.1 M KCl, 1% Triton XlOO, 0.3mM PMSF, OJ ⁇ g/ml Pepstatin, 2 ⁇ g/ml Aprotinin, 2 ⁇ g/ml Leupeptin for 30min. at 4 0 C and spun at 100 1 OOOg for 40min. 2 g of rat brain was lysed in a volume of 5 ml, yielding a concentration of 8 mg/ml.
- Brain slices of the somatosensory cortex from NaVPA treated and control animals were homogenized in sucrose buffer (0.32M sucrose, 1OmM Hepes protease inhibitors 0.3 mM PMSF, 0.7 ⁇ g/ml Pepstatin, 2 ⁇ g/ml Aprotinin, 2 ⁇ g/ml Leupeptin) at 800rpm with an eppendorf pellet pistel. Triton was added to a final concentration of 1% and the homogenate rolled for 5min. at 4°C. The homogenate was spun 5min. at full speed and 4 0 C.
- Sample concentrations were equalized by diluting with 1% SDS and loading buffer 4X (16% glycerol, 8% SDS, 3% Tris, 20% beta-mercaptoethanol, and 0.5% bromophenol blue) to yield a final protein concentration of 1.33 mg/mL.
- Rats were deeply anesthetized with pentobarbital (65 mg/200-350 gm). Rats were then perfused transcardially with 50 ml of 0.1 M sodium phosphate with 1.0 niL of heparin (1000 units/mL), pH 7.4 followed by 100 ml of 4% paraformaldehyde in 0.1 M sodium phosphate, pH 7.4. Brains were removed from the skull and post-fixed for 24 hr at 4°C before being transferred to 20% sucrose in 0.1 M sodium phosphate, pH 7.4, for 48 hr at 4 0 C. Brains were frozen in powdered dry ice and stored at -20° C.
- Coronal sections (40 ⁇ M) were cut in a cryostat, collected in ethylene-glycol cryoprotectant, and stored at -80° C until further processing.
- sections for each treatment group were processed at the same time, such that each batch contained tissue from saline treated rats and valproic acid treated rats. The tissue was allowed to come to room temperature for one hour. Sections were rinsed 3 X 3 minutes in tris-buffered saline (TBS) with 0.1% Tween 20 (TBST) and 0.1 % Triton followed by a 20 minute rinse in 0.7% H2O2 diluted in TBST.
- TBS tris-buffered saline
- TBST 0.1% Tween 20
- Triton 0.1 % Triton
- Sections were rinsed 3 X 3 minutes in TBST and placed in blocking buffer for 1 hr at 22 0 C.
- the blocking buffer consisted of 10% normal serum in TBST. Sections were incubated overnight at 4°C in primary antibody diluted in 10% normal rabbit serum in TBST. After sections were washed in TBST, they were processed using a standard secondary detection system with ABC and nickel DAB.
- Neurons were counted bilaterally at no less than two different anatomic levels for each anatomic structure (medial PFC, primary somatosensory cortex, and secondary somatosensory cortex).
- Bright-field images of immunoreactive-postive soma were captured using a digital camera and automatically counted using a computerized system.
- the Applicants for the first time ever performed experiments to examine the cellular, synaptic and local circuit changes in an animal model of autism as well as novel behavioral experiments.
- the applicants also carried out genomic and proteomic studies which reveal the molecules and genes involved in the synaptic, cellular, circuit abnormalities as well as those underlying the behavioral alterations in memory, perception and attention.
- FIG. 2 shows a dose-response curve in which the neocortical microcircuit was stimulated in multiple sites at progressively greater stimulus strengths. The response increases to produce a sigmoid response curve.
- the autistic microcircuit was hyper-excitable in terms of both excitatory and inhibitory voltage as can be seen by the generation of more voltage at lower stimulus strengths and reaching peak responses considerably higher than in control animals (Figure 2).
- NMDA receptors are special forms of excitatory transmitter receptors activated by glutamate and are essential for many memory processes. During intense stimulation, synapses are fully activated and it is possible to record the amount of NMDA triggered current that the NCC can produce.
- the NMDA receptor channel allows the flow OfNa + , K + and Ca 2+ ions. When the cell is held at high potentials then only Ca 2+ influx can be detected. Additionally NMDA receptors open neighbouring Calcium channels to allow additional Calcium inflow. Applicants found that the amount of NMDA receptor-mediated current at high potentials is greatly increased in Autism indicating a massive enhancement of Ca 2+ ion influx triggered by NMDA receptors (Figure 6).
- Applicants carried out a course-grained gene expression analysis in which proteins from somatosensory cortex from controls and autistics were assayed using SDS-page electrophoresis and immunoblotting. They found a number of protein deficits, but some are particular highly relevant to the hyperconnectictivity disorder. In particular, the subunits 2A and B that are required to build special subtypes of NMDA receptors were up regulated. Another protein alteration is relevant to the hyper-learning disorder: Applicants have shown increased levels of CamKII, a key kinase involved in learning and memory processes, in the treated rats. These results support the excessive learning due to increased intracellular calcium levels (Fig 5).
- This hyperconnectivity of local microcircuits of neurons may be throughout the brain, but the effects in the neocortex will be devastating for the cardinal cognitive deficits in autism that result from hyper-perception, attention and memory.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention concerns a method for treating and/or preventing a Pervasive Developmental Disorder in a subject in need thereof comprising the step of modulating the synaptic connectivity in the neocortex by administering a therapeutically effective amount of a composition capable of reducing memory, perception and/or attention.
Description
Methods for treating and/or preventing Pervasive Developmental Disorders in a subject.
FIELD OF THE INVENTION
The present invention concerns a method for treating and/or preventing Pervasive Developmental Disorders in a subject in need thereof comprising the step of modulating the synaptic connectivity in the neocortex by administering a therapeutically effective amount of a composition capable of reducing memory, perception and/or attention performance.
BACKGROUND OF THE INVENTION
Autism spectrum disorders is now recognized as a major neurological developmental disorder affecting children starting during the first 5 years of life. Leo Kanner, in 1943, first described children that do not make eye contact, are impaired in language, apparently lack the need or skill for social interaction, indulge in repetitive behavior, display sensory perceptual abnormalities, are extremely sensitive to novel situations or environments displaying a resistance to change, and they do not seek comfort during stress. Most autistics also suffer from severe sensory distortions, gastrointestinal and eating disorders as well as sleep, movement, metabolic and immune disorders, and about half experience epileptic episodes. Autism is a broad-spectrum disorder with a wide range of symptoms.
Classically autism is considered to be on one end of the spectrum of an even broader category of Pervasive Developmental Disorders (PDD). Some types of autism that have been described include Typical Autism, Atypical Autism/PDD, Autistic Savants, Asperger's Syndrome, and autism associated with Kanner's Syndrome, fragile X, Rett and Down's syndromes. The overall prevalence of the broadest category of abnormal developmental progression is thought to occur in 1 in 300 children, 1 in 500 children will be born on the autistic spectrum and 1 in 1000 with severe autism. Autism has a clear genetic predisposition which is based on the fact that the probability of an identical twin having autism is around 50% as apposed to 0.5% in the general population. The probability of autism in Down's Syndrome is also 10%. It seems that the genes involved in these developmental disorders do not directly cause these autistic spectrum disorders, but impart a vulnerability to external triggers, especially teratogens during pregnancy. The wide range of possible symptoms have led researches to speculate multiple
triggers including viruses, vaccinations, bacterial, immune deficiency, gastrointestinal disorders, toxic insults at neurologically sensitive periods of brain development, and many more.
Typically, developmental disorders are thought to be caused by impaired cognitive functions. While brain imaging studies have most often implicated the cerebellum in autism, abnormalities in many other brain areas have been reported, including limbic areas, thalamus, hypothalamus, the brain stem, the neocortex, and even the pineal gland. In accordance with the spectrum of symptoms and potential causes of autism, a variety of intervention treatments have emerged, including behavioral, sensory, sensory-motor integration, cognitive enhancing therapies, and various nutritional and pharmacological treatments. Aside from helping by acting on selective symptoms, the efficacy of pharmacological treatments is, in general, very poor. While many children with autism do improve to some extent with behavioral intervention programs, most autistics will be unable to live independently and more than half will never learn to speak correctly. While the autistic phenotype is highly heterogenous, common features are high level cognitive abnormalities in memory, perception and attention. Surprisingly, Applicants have shown that the autistic brain is not impaired in many key cognitive abilities, but rather that the handicap arises from excessive brain functions and capabilities. In particular, behavioral experiments have revealed that memory processes are enhanced making it difficult for the autistic to uncouple prior associations leading to rigidity in social adaptation and communication. Perceptual processes are enhanced making the autistic overly sensitive to sensory stimulation and attention is enhanced, making autistics inflexible to shifting attention easily and fluidly in a rapidly changing sensory world. Electrophysiological experiments have also revealed a massive increase in the probability of synaptic connections between pyramidal neurons in different neocortical layers indicating that the local microcircuitry in the autistic neocortex is hyper-connected. The electrophysiological experiments also reveal an altered and greatly enhanced form of synaptic plasticity, which is thought to underlie memory formation as well as a large increase in the amount of NMDA-receptor triggered currents, which causes plasticity. Protein assays revealed an increase in the NMDA receptor levels in particular subunits NR2A and NR2B, indicating that there is a massive increase in currents that can be triggered by NMDA receptors in autism. Electrophysiological data also show a compensatory decrease in excitability of neurons.
There has been some progress in the treatment of Pervasive Developmental Disorders (PDD), in particular autism, by using N-rnethyl-D-aspartate receptor (NMDA) antagonists such as ketamine or dextrometorphan. For example, U.S. Patent 6,362,226 discloses a method of treating autism in a patient, said method comprising administering to the patient an effective amount of a glutamine level reducing agent, a glycine level reducing agent or combinations thereof. Optionally, an NMDA receptor antagonist can also be administered to the patient in combination of a glutamine level reducing agent and/or glycine level reducing agent.
In the same way, U.S. Patent 4,994,467 relates to a method that is provided for treating autism and other pervasive developmental disorders in children by the administration of a therapeutically effective amount of an NMDA receptor antagonist.
However, the use of these NMDA receptor antagonists is not ideal. NMDA antagonism by, for example, Ketamine is a commonly used aneasthetic and low doses of NMDA antagonism can cause dissociative disorders and psychoses. U.S . Patent Application N° 2004/0067978 Al discloses the use of mGluR antagonists, preferably selective for mGluR5 receptors, in the hippocampus, for the treatment and prevention of disorders, including Fragile X, autism, mental retardation, schizophrenia and Down's Syndrome. However, this disclosure is based on the finding that mGluR-5 receptor activation causes depression of synaptic connections in the neocortex and they have the goal of trying to increase synaptic plasticity and memory processes. The applicants have found that the opposite is required in the treatment of autism. A possible treatment for the autistic hippocampus would be to activate rather than block the mGlur-5 receptor in the hippocampus. The applicants also found that mGlur-5 receptor results in very different effects in different brain regions. Activation of the group I metabotropic receptors, including mGluR-5, in the neocortex, underlies the formation and disconnections of synaptic connections and they found that antagonizing the mGluR-5 receptor can retard this circuit remodeling in the neocortex. Antagonizing mGlur-5 receptors, specifically in the neocortex, is therefore a good potential treatment for autistic neocortex, and for a very different reason than proposed by U.S. Patent Application N° 2004/0067978 Al. In addition, the treatment would be required chronically from as early after birth as possible to retard the formation of circuits and prevent the hyperconnectivity and resulting symptoms.
Despite the disclosure of the foregoing patents and patent applications, there remains therefore significant room for improvement in the treatment of Pervasive Developmental Disorders and in particular autism.
Therefore, it is an object of the present invention to provide new treatment modalities for the treatment of Pervasive Developmental Disorders which have a good safety profile, a good specificity, only low or no side effects and the possibility to retreat, whenever necessary.
This object has been achieved by providing a method for treating and/or preventing a Pervasive Developmental Disorder in a subject in need thereof comprising the step of modulating the synaptic connectivity in the neocortex by administering a therapeutically effective amount of a composition capable of reducing memory, perception and/or attention by either blocking synaptic strengthening, enhancing synaptic weakening, reducing synapse formation, enhancing synaptic breakdown, decreasing network excitability, increasing the level of network inhibition, reducing the supply of dopamine to the neocortex, blocking calcium channels, reducing intracellular calcium levels, and/or blocking the somatostatin receptor 2.
SUMMARY OF THE INVENTION
The present invention concerns a method for treating and/or preventing a Pervasive
Developmental Disorder in a subject in need thereof comprising the step of modulating the synaptic connectivity in the neocortex by administering a therapeutically effective amount of a composition capable of reducing memory, perception and/or attention by either blocking synaptic strengthening, enhancing synaptic weakening, reducing synapse formation, enhancing synaptic breakdown, decreasing network excitability, increasing the level of network inhibition, reducing the supply of dopamine to the neocortex, blocking NMDA receptors, blocking calcium channels, reducing intracellular calcium levels, and/or blocking the somatostatin receptor 2. A further object of the present invention is to provide a kit for the treatment for a
Pervasive Developmental Disorder comprising a therapeutically effective amount of a composition capable of reducing memory, perception and/or attention and instructions to use.
Another object of the present invention is to provide a diagnostic kit. The kit includes antibody markers to perform immunohistochemical stainings to test for the alteration in specific proteins levels and gene expression changes found in the autistic brain.
Other objects and advantages will become apparent to those skilled in the art from a review of the ensuing detailed description, which proceeds with reference to the following illustrative drawings, and the attendant claims.
BRIEF DESCRIPTION OF THE FIGURES
Figures 1 depict the Hyperconnectivity. Fig. 1 a shows the increased probability of direct connection between layer 5 pyramidal cells (PCs) in a cluster (P = 0.008, Chi-square). Fig. 1 b, No hyperconnectivity at longer distances (P = 0.52, Chi-square). Fig. 1 c represents the parameters of the synaptic connection with a model of dynamic synaptic transmission: the absolute synaptic strength A (P = 0.023, Student's t-test), the probability of release Pr (P = 0.17, Student's t-test), the time constant of synaptic depression!) (P = 0.61, Student's t-test). The weakened synapses were consistent with the decreased synaptic conductances evoked by minimal stimulation (n = 36 cells (control), 45 cells (treated); P < 0.002 for all stimulation amplitudes, Student's t-test). Fig. 1 d shows the increased number of di-synaptic connections between thick tufted layer 5 PCs (via interneuron (M) between the two PCs) (P < 0.0001, Chi-square). Data show mean ± s.e.m.
Figures 2 depict the Hyper-reactive network. Fig. 2 a represents the MEA stimulation with 16 electrodes (50Hz Poisson train, 300 ms) in layer 5 thick tufted pyramidal neurons. Fig. 2 b, shows the integral of responses to MEA stimulation in current-clamped PCs as a function of stimulation amplitude. Fig. 2 c represents the number of spikes elicited by the MEA stimulation as a function of the stimulation amplitude. Fig. 2 d represents the number of network events elicited by the stimulation as a function of stimulation amplitude. The upper traces represent the response of a whole-cell patched layer 5 pyramidal neuron, with an emphasis on what is measured for each graph. Fig. 2 e shows the MEA stimulation with 16 electrodes (50Hz Poisson train, 300 ms) in layer 2/3 pyramidal neurons. Fig. 2 f, g, h show the charge responses to MEA stimulation: global (Vhoid = -80 mV) (b), excitatory (Vhoid = -57 mV) (c) and inhibitory (Vhoid = +10 mV) (d) response curves. The upper traces represent the
responses of the whole-cell patched layer 2/3 pyramidal cells. The grey area is the charge measured for the dose response curves. Data show mean ± s.e.m. (*, P < 0.05; **, P < 0.01).
Figures 3 depict the Hypoexcitability of pyramidal cells. Fig. 3 a shows an example of currents injected and corresponding voltage measurements in layer 2/3 pyramidal cells from control (blue) and VPA-treated (red) rats. Mean of injected current to threshold for layer 2/3 (P = 0.00001) and layer 5 cells (P = 0.05). Fig. 3 b is an Example of the current-frequency (IF) curve for layer 2/3 pyramidal cells. Mean of IF slope (linear fit) for layer 2/3 (P = 0.011), and layer 5 cells (P = 0.019). Fig. 3 c is an example of wider second action potential of layer 2/3 cells. Mean of second action potential half width for layer 2/3 (P = 0.049) and layer 5 cells (P = 0.17). All statistics were made with the Student's Mest; data show mean ± s.e.m.
Figures 4 represent the Anatomy of layer 5 pyramidal cells. Fig. 4 a shows an example of Sholl analysis of a layer 5 thick tufted pyramidal cell. Fig. 4 b represents the Sholl analysis of the axonal (ASI; P = 0.62, Kolmogorov-Smirnoff) and dendritic (DSI; P = 0.23, Kolmogorov- Smirnoff)) tree intersections. Fig. 4 c shows the surface of the soma (406 ± 40 μm2 for control, 340 ± 29 μm2 for treated; P = 0.12, Student's f-test). Bouton density (0.15 ± 0.02 μm" 1 for control, 0.12 ± 0.01 μm"1 for treated; P = 0.20, Student's t-test). Spine density (0.13 ± 0.01 μm'1 for control, 0.15 ± 0.02 μm"1 for treated; P = 0.48, Student's r-test). Fig. 4 d is a picture of layer 5 somatosensory cortex, as used for pyramidal cell density counting. Thick tufted pyramidal cells were recognized by their characteristic apical dendrite, soma shape and size. The density was calculated in a volume of 180 μm x 180 μm x 30 μm. Fig. 4 e represents layer 5 pyramidal cell density (52 ± 1 xlO3 mm"3 for control, 54 ± 2 xlO3 mm"3 for treated; P = 0.28, Student's t-test). Fig. 4 f is an Example of the reconstruction of a connected pair of layer 5 pyramidal cells in the VPA-treated rats. The green stars represent the putative synapses. Data show mean ± s.e.m.
Figures 5 depict the enhanced CarnKII, NR2A and NR2B protein expression levels. Examples of Western blot gels and mean values reported as percentage of control. Fig. 5 a shows Western blots of CREB (n = 6, 7), CamKH (n = 11, 11) and ERK (n = 12, 12). Fig. 5 b, shows Western blots of AMPA receptor subunits GIuRl (n = 8, 9), GluR2 (n = 8, 8) and GluR3 (n = 8, 8). Fig. 5 c shows Western blots of NMDA receptor subunits NRl (n = 8, 8), NR2A (n = 8, 8), NR2B (n = 7, 8). Data show mean ± s.e.m. (*, P < 0.05; **, P < 0.01).
Figures 6 represent the Enhanced NMDA mediated synaptic currents. Fig. 6 a shows the Experimental scheme and example of response in the postsynaptic cell before (total) and after blocking of AMPA receptors with NBQX (NMDA). The difference between the control and NMDA traces give the AMPA trace. Fig. 6 b shows the Peak currents of AMPA and NMDA responses. Fig. 6 c represents the Charge of total, NMDA and AMPA traces; percentage of NMDA ( = NMD A/total) and AMPA/NMDA ratio. Data show mean ± s.e.m. (*, P < 0.05; **, P < 0.01).
Figures 7 depict the Enhanced postsynaptic plasticity. Fig. 7 a,b,c show the LTP with extracellular stimulation in layer 2/3 pyramidal neurons, a, Experimental scheme, pairing protocol and example of mean response in a patched cell, before and after pairing . b, Example of response amplitude as a function of time. The grey line represents the timing of the pairing protocol, c, Mean of percentage increase in the amplitude of the response to extracellular stimulation after pairing. Fig. 7 d, e show the LTP in direct connections between layer 5 pyramidal neurons, d, Experimental scheme, pairing protocol and example of mean responses in the postsynaptic cell before and after pairing, e, Mean of percentage change after pairing of the absolute synaptic efficacy A, the probability of release Pr and the time constant for depression D. The absolute values of A, Pr and D before and after pairing are displayed in Supplementary Fig 3. Data show mean ± s.e.m. (*, P < 0.05).
Figure 8 shows enhanced fear memories after 1, 34 and 69 days and shows reduced ability to extinguish fear memories after 3 days of de-conditioning .
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to a method for treating and/or preventing a Pervasive Developmental Disorder in a subject in need thereof comprising the step of modulating the synaptic connectivity in the neocortex by administering a therapeutically effective amount of a composition capable of reducing memory, perception and/or attention by either i) blocking synaptic strengthening, ii) enhancing synaptic weakening,
iii) reducing synapse formation, iv) enhancing synaptic breakdown, v) decreasing network excitability, vi) increasing the level of network inhibition, vii) reducing supply of dopamine to the neocortex, viii) blocking the somatostatin receptor 2, wherein compositions i) to viii) are administered separately or concurrently in different combinations.
As used herein, "a" or "an" means "at least one" or "one or more."
The term "comprising" is generally used in the sense of include, that is to say permitting the presence of one or more features or components.
"Pervasive Developmental Disorder", "Pervasive Developmental Disorders" or
"PDD" refer to a group of disorders characterized by delays in the development of socialization and communication skills. Parents may note symptoms as early as infancy, although the typical age of diagnoses is before 3 years of age. Symptoms may include problems with using and understanding language; difficulty relating to people, objects, and events; unusual play with toys and other objects; difficulty with changes in routine or familiar surroundings, and repetitive body movements or behavior patterns.
Usually, the PDD to be treated are selected from the group comprising Fragile X, autism, mental retardation, schizophrenia and Down's Syndrome.
Particularly, the PDD is autism. In such case, autism comprises Typical Autism, Atypical Autism/PDD, Autistic Savants, Asperger's Syndrome, and autism associated with Kanner's Syndrome, fragile X, Rett and Down's syndromes.
"Concurrently" as used herein means that the compositions of the invention are coadministered either by administering individual compositions or by administering a cocktail of said compositions.
As used herein "neocortex" refers to the evolutionary newest brain region that comprises almost 80% of the human brain. It is the upper mantel covering the paleo and archi
cortices. It is the part of the brain the processes sensations, motor actions and high level cognitive functions such as perception, attention and memory.
Usually, the term "subject" refers to any animal classified as a mammal including humans, domestic and farm animals, and zoo, sports or pet animals, such as dogs, horses, cats, cows, monkeys, etc. Preferably, the mammal is a human.
As used herein, the various forms of the term "modulating" include stimulation (e.g. increasing or upregulating a particular response or activity) and inhibition (e.g. decreasing or downregulating a particular response or activity).
"Synaptic connectivity" refers to the connections formed between neurons to transmit information. A single synaptic connection is comprised of multiple synapses, typically 5-10.
"Synaptic plasticity" refers to changes in the strength of synaptic connections. Long term synaptic plastic changes are also called either Long Term Potenatiation (LTP) or Long Term Depression (LTD) depending on the direction of the change.
"Administering", as it applies in the present invention, refers to contact of a pharmaceutical, therapeutic, diagnostic agent or composition, to the subject, preferably a human.
A "therapeutically effective amount" is an amount effective to ameliorate or prevent the symptoms, or prolong the survival of, the subject being treated. Determination of a therapeutically effective amount is well within the capabilities of those skilled in the art, especially in light of the detailed disclosure provided herein.
An "agonist" is a molecule which activates a certain type of receptor. For example, glutamate molecules act as agonists when they excite excitatory amino acid (EAA) receptors.
By contrast, an "antagonist" is a molecule which prevents or reduces the effects exerted by an agonist on a receptor.
Many naturally occurring neurotransmitters are agonists, since they activate the receptors they interact with. By contrast, artificial and/or exogenous drugs may be agonists or antagonists. For example, NMDA antagonists are drugs that can suppress excitatory activity of
glutamate or glycine at NMDA receptors.
As used herein a "blocker" refers to an antagonist which is a chemical compound that binds to a receptor or ion channel to prevent its function.
Although agonist and antagonist drugs are generally thought to interact directly with receptors to achieve their effects, such effectivity may not result from direct interaction but may involve intermediate steps or compounds.
Hence, the present invention is not limited to mechanisms acting directly on affected receptors involved or thought to be involved in autistic disorders. Rather, any effect of the drugs on receptors or more generally on metabolism or symptoms of the disorder is contemplated as part of the present invention.
The term "drug" refers to chemical, peptidic or natural compounds which, when incorporated in the composition of the invention, or even alone, are capable of reducing memory, perception and/or attention by either blocking synaptic strengthening, enhancing synaptic weakening, reducing synapse formation, enhancing synaptic breakdown, increasing network excitability, decreasing the level of network inhibition, reducing supply of dopamine to the neocortex, blocking alpha 1 noradrenergic receptors, or blocking the somatostatin receptor 2. There are several classes of drugs of different origin and with different modes of action e.g. they can be agonists, antagonists, inhibitors, enhancers, blockers or down regulators.
As supported in the examples, Applicants have completed a number of studies which allow a better understanding of the hyper connectivity associated with PDD. Applicants have shown that hyperconnectivity is not due to excessive growth of axons or dendrites or boutons or synapses. Instead a novel form of target dominance seems to be activated.
The Target Dominance (TD) mechanism determines the number of target neurons contacted by a neuron. The higher the target dominance the more strongly the network of neurons are coupled causing the network to become autonomously active and difficult to control by regulatory mechanisms, such as those from the prefrontal cortex that control executive functions. The predicted consequence is that the local microcircuits of the neocortex
become overly sensitive, hyper-reactive, autonomously active and difficult to control. At the cognitive level this is predicted to translate into severe abnormalities in perception, attention and memory. The perceptual abnormality is proposed to be due to oversensitivity and over- reactivity of the local circuits. The attention abnormality is proposed to be due to the autonomous local circuits which can not be controlled by attention mechanisms. The memory abnormality is proposed to be due excessive storage of memories in the hyper-connected networks causing behavioral rigidity and inflexibility to new environments.
There is no generalized hypertrophy of synapses to cause an increase in synaptic connections on existing neurons and add synapses onto new targets, instead many more neurons are contacted with less synapses on each neuron. The mechanism of Target Dominance is therefore activated to contact as many neurons as possible. Accordingly, reversing this mechanism is a man novel strategy for treating PDD and in particular autism.
Applicants have also shown which key molecules are involved in the TD mechanism. Additionally, they have shown that it is possible to change the target profile of neurons, i.e. the set of neurons that each neuron targets. Experience and intense excitation of the circuit (equivalent to an intense experience) can enhance TD resulting in hyperconnectivity. Accordingly, Applicant's can therefore induce hyper-connectivity in the normal brain with intense activation.
In normal life, this is likely to be a transient process during which memories can be stored more effectively, but in the case of Autism, the circuit seems to always be in this primed state. Since the excitation that causes the hyper-connectivity is mediated by glutamate the receptors that mediate TD are novel therapeutic targets to treat PDD.
Usually, the therapeutically effective amount of a composition of the present invention capable of reducing memory, perception and/or attention by blocking synaptic strengthening comprises a drug selected from the group comprising a muscarinic receptor antagonist, acetylcholin esterase enhancer, N-methyl-D-aspartate (NMDA) receptor antagonist, second messenger blocker, calcium channel blocker, group IE metabotropic glutamatergic receptor agonist (group IH mGluR), intracellular calcium buffer molecule and/or a combination thereof.
Exemplary muscarinic receptor antagonists, aimed at reducing the supply of acetylcholine to the neocortex, comprise, but are not limited to:
Muscarinic antagonists having a selectivity for muscarinic receptors Mi > ML2; e.g. Nitrocaramiphen hydrochloride (2-Diethylaminoethyl l-(4- nitrophenyl)cyclopentanecarboxylate hydrochloride),
Muscarinic M^ antagonists: e.g. 4-DAMP (ll>l-Dimethyl-4-diphenylacetoxypiperidinium iodide),
Antagonist-receptor complex stabilisers: e.g. W-84 dibromide (Hexamethylene-bis-[dimethyl-(3- phthalimidoρropyl)ammonium]dibromide),
Muscarinic antagonist: e.g. Ipratropium bromide (e«Jo,j>'«X±)-3-(3-Hydroxy-l-oxo-2-phenylpropoxy)-8-methyl-8- (l-methylethyl)-8-azoniabicyclo[3.2.1]octane bromide),
M4 selective muscarinic receptor antagonist: e.g. Tropicamide (jV-Ethyl-3-hydroxy-2-phenyl-N-(pyridinylmethyl)propanamide)5
Selective Mj_ muscarinic antagonist: e.g. Pirenzepine dihydrochloride (5,ll-Dihydro-l l-[(4-methyl-l-piperazinyl)acetyl]-6/i- pyrido[2,3-b][l,4]benzodiazepin-6-one dihydrochloride),
Selective M? antagonists: e.g. AF-DX 116 (l l-[[2-[(Diethylamino)methyl]-l-piρeridinyl]acetyl]-5,ll-dihydro-6H"- pyrido[2,3-b][l,4]benzodiazepin-6-one) or Otenzepad,
Potent selective M^ antagonists: e.g. Telenzepine dihydrochloride (4,9-Dihydro-3-methyl-4-[(4-methyl-l-piperazinyl)acetyl]- 10/7-thieno[3 ,4-b] [ 1 , 5]benzodiazepin- 10-one dihydrochloride),
Selective high affinity muscarinic Mi receptor antagonist (Kt = 0.94 nM).
Potent MTZM4 antagonists: e.g. AF-DX 384 (ll-ttl-tCDiethylamino^nethy^-l-piperidinyllacetylJ-SJl-dihydro-όH- pyrido[2,3-b] [ 1 ,4]benzodiazepin-6-one) or Otenzepad,
Non-selective muscarinic antagonists: e.g. Scopolamine hydrobromide ((α,S)-α-(Ηydroxymethyl)benzeneacetic acid
(1 a,2b,4b, 5α,7&)-9-metliyl-3-oxa-9-azatricyclo[3.3.1.02,4]non-7-yl ester hydrobromide),
M?-selective antagonists: e.g. (5)-(+)-Dimetbindene maleate (iV,iV-Dimethyl-3-[(15)-l-(2-pyridinyl)ethyl]-lH-indene-2- ethanamine maleate),
Enantiomer that is a subtype-selective M2 muscarinic receptor antagonist (pKt values are 7.08, 7.78, 6.70 and 7.00 for Mi, M2, M3 andM4 receptors respectively). Also Hi histamine receptor antagonist (pKt = 7.48).
Selective M4 antagonists: e.g. PD 102807 (356a,ll,14-Tetrahydro-9-methoxy-2-methyl-(12H)-isoquino[l,2- 6]pyrrolo[3,2:/][l,3]benzoxazine-l-carboxylic acid, ethyl ester),
Selective M4 muscarinic receptor antagonist. ICso values are 91, 6559, 3441, 950 and 7412 nMfor human M4, Mj, M2, M3, and Ms receptors respectively
Other Muscarinic receptor inhibitors such as Type 1 and Type 2 inhibitors.
Modulators of cholinergic function, usually acetylcholine esterase enhancers: such as Cholinesterase inhibitor (e.g. Ambenonium dichloride, Galanthamine hydrobromide, Tacrine hydrochloride), ACh release Stimulators (e.g. MR 16728 hydrochloride, Cisapride), Cholinesterase inhibitor (e.g. Physostigmine hemisulfate), ACh transport inhibitor (e.g. (±)- Vesamicol hydrochloride), Presynaptic cholinergic modulator (e.g. PG-9 maleate), Presynaptic cholinergic modulator (e.g. SM-21 maleate).
Exemplary mGluR Group HI (mGluR 4, 6, 7 and 8) agonists comprise, but are not limited to:
L(+)-2-amino-4-phosρhonobutyric acid (L- AP4), (S)-3,4-dicarboxyphenylglycine (DCPG), selective mGluR8 subunit (a) agonist,
(R,S)-4-Phosρhonophenylglycine ((R5S)-PPG),
(lS,3R,4S)-l-Aminocyclopentane-l,2,4-tricarboxylic acid (ACPT-I), a selective agonist at the group III mGluR4 subunit (a),
(3RS,4RS)-1- Aminocyclopentane-l,3,4-tricarboxylic acid ((±)-ACPT IH).
Applicant have shown that the NMDA receptor does not determine TD, but determines the strength of existing synapses. It is well known that NMDA receptors control the strength of synapses, but it was not known that target selection can be made without NMDA. The involvement of NMDA receptors in plasticity of existing synapses is therefore likely to be important in the memory processes after neurons are contacted and in the case of Autism after the TD mechanism has been activated. Indeed, Applicant's shown that the plasticity was much stronger at autistic synapses and that 1) the NMDA receptor-mediated current is massively increased (functional index of NMDA receptor activity), that 2) the phosphorylation of the NRl NMDA receptor subunit (the obligatory protein subunit) is greatly enhanced in the animal model of autism, 3) and that the 2A and 2B subunits are overexpressed.
Exemplary NMDA receptor antagonists comprise, but are not limited to:
NMDA Site antagonists such as:
DL- AP7 (DL-2-Amino-7-phosphonoheptanoic acid),
DL-AP5 (DL-2-Amino-5-ρhosphonopentanoic acid), D-AP5 (D-(-)-2-Amino-5-phosphonopentanoic acid), L-AP5 (L-(+)-2-Amino-5-phosphonopentanoic acid), D-AP7 (D-(-)-2-Amino-7-phosphonoheptanoic acid),
(RS)-CP? ((i?5)-3-(2-Carboxypiperazin-4-yl)-proρyl- 1 -phosphonic acid), (R)-CP? (3-((/?)-2-Carboxypiperazin-4-yl)-propyl- 1 -phosphonic acid),
Shows some selectivity for NR2A-containing receptors
(i?)-4CPG ((i?)-4-Carboxyρhenylglycine), .
LY 235959 ([SiS-CSα^α^ό^αα^-Decahydro-β-CphosphonomethyOSisoquinolinecarboxylic acid))
Competitive NMDA antagonists such as:
CGS 19755 (cw-4-[Phosphomethyl]-piperidine-2-carboxylic acid),
SDZ 220-581 ((^-α-Amino^'-chloro-S-CphosphonomethyOt^r-biphenyy-S-propanoic acid),
SDZ 220-040 ((5)-α-Amino-2',4'-dichloro-4-hydroxy-5-(phosρhonomethyl)-[l,r-biphenyl]- 3 -propanoic acid),
CGP 37849 ((E)-(±)-2-Amino-4-methyl-5-phosphono-3-pentenoic acid),
CGP 39551 ((E)-(±)-2-Amino-4-methyl-5-pliosphono-3-pentenoic acid ethyl ester)
Glycine Site Antagonists such as: CNQX (6-Cyano-7-nitroquinoxalme-2,3-dione),
7-Chlorokynurenic acid (7-Chloro-4-hydroxyquinoline-2-carboxylic acid),
ACBC (l-Aminocyclobutane-l-carboxylic acid),
(S)-(-)-HA-966 ((S)-(-)-3-Ammo-l-hydroxypyrrolidin-2-one),
5,7-Dichlorokynurenic acid (5,7-Dichloro-4-hydroxyquinoline-2-carboxylic acid), L-701 ,252 (7-Chloro-3-(cycloρropylcarbonyl)-4-hydroxy-2(lH)-quinolinone),
L-689,560 (trans-2-Carboxy-5,7-dichloro-4-phenylaminocarbonylamino- 1 ,2,3 ,4- tetrahydroquinoline),
Felbamate (2-Phenyl-l,3-propanedioldicarbamate),
L-701,324 (7-Chloro-4-hydroxy-3-(3-ρhenoxy)ρhenyl-2(lH)-quinolinone), CGP 78608 hydrochloride ([(lS)-l-[[(7-Bromo-l,2,3,4-tetrahydro-2,3-dioxo-5- quinoxalinyl)methyl]amino]ethyl]phosphonic acid hydrochloride).
Ion Channel Antagonists such as: (±)-l-(l,2-Diphenylethyl)piperidme maleate,
Memantine (hydrochloride 3,5-Dimethyl-tricyclo[33 J J3,7]decan-l-amine hydrochloride), Dizocilpine ((+)-MK 801 maleate),
(5S, 10R)-(+)-5-Methyl- 10, 1 l-dihydro-5H-dibenzo[a,d]cyclohepten-5, 10-imine maleate,
(-)-MK 801 maleate ((5R,10S)-(-)-5-MethyM0,ll-dihydro-5H-dibenzo[a,d]cylcoheρten- 5,10-imine maleate),
Loperamide hydrochloride (4-(4-Chloroρhenyl)-4-hydroxy-N,N-dimethyl-a,a-diphenyl-l- piperidinebutanamide hydrochloride),
Also a Ca2+ channel blocker; at low micromolar concentrations it blocks broad spectrum neuronal HVA Ca2+ channels and at higher concentrations it reduces Ca2+ flux through NMDA receptor operated channels Remacemide hydrochloride (2- Amino-N-(1 -methyl- l,2-diphenylethyl)acetamide hydrochloride),
Uncompetitive NMDA receptor antagonist; blocks ion channel and allosteric modulatory site (IC50 = 8-68 mM).
IEM 1460 (N,N,N,-Trimethyl-5-[(tricyclo[3.3.1.13,7]dec-l-ylmethyl)amino]-l- pentanaminiumbromide hydrobromide), shows selectivity between subtypes, blocking GluR2 subunit-lacking (Ca2+ -permeable) cerebellar receptors more potently than GluR2-containing hippocampal receptors (IC so values are 2.6 and 1102 mM respectively.
Norketamine hydrochloride (2-Amino-2-(2-chlorophenyl)cyclohexanone hydrochloride), (K1 = 3.6 JtM for displacement Of[3H]-MK 801 in rat brain).
N20C hydrochloride (2-[(3,3-Diphenylpropyl)amino]acetamide hydrochloride)
Selective, non-competitive NMDA receptor antagonist (IC50 — 5 mM); binds to the receptor- associated ion channel and prevents glutamate-induced Ca2+ influx.
Polyamine Site Antagonists such as:
N-(4-Hydroxyphenylacetyl)spermine N-(N-(4-Hydroxyphenylacetyl)-3-ammoρropyl)-(N'-3- aminopropyl)- 1 ,4-butanediamine,
N-(4-Hydroxyphenylproρanoyl) spermine trihydrochloride (N-(N- (4Hydroxyphenylpropanoyl)-3-aminopropyl)-(N'-3-ammopropyl)-l,4-butanediamine trihydrochloride ),
Arcaine sulfate (N,N'-1,4-Butanediylbisguanidine sulfate),
Ifenprodil hemitartrate (2-(4-Benzylpiperidino)-l-(4-hydroxyphenyl)-l-propanol hemitartrate),
Synthalin sulfate (N5N'- 1 , 10-Decanediylbisguanidine sulfate), Eliprodil (a-(4-Chlorophenyl)-4-[(4-fluorophenyl)methyl]-l-piperidineethanol)
Non-competitive NR2B-selective NMDA antagonist. Also s ligand and Ca2+ channel blocker.
Other NMDA selective Antagonists such as:
Ro 25-6981 maleate ((αR,βS)-α-(4-Hydroxyphenyl)-β-methyl-4-(ρhenylniethyl)-l- piperidinepropanol maleate) Potent and selective activity-dependent blocker of NMDA receptors that contain the NR2B subunit. IC50 values are 0.009 and 52 aMfor cloned receptor subunit combinations NR1C/NR2B andNRlC/NR2A respectively.
Bilobalide, a constituent of Ginkgo Biloba, Lipocortin-1, Cerebral Fluid Zinc level elevators
Spermidines.
Preferably, the NMDA antagonists are selective for NMDA receptor subunits NR2A and/or NR2B.
Applicants have also shown that blocking group 3 metabotropic glutamate receptors
(mGluRs) while intensely activating the circuit, causes synapses to get stronger indicating that these receptors normally serve to keep synapses from becoming to too strong. Activating these receptors therefore prevent the hyper-plasticity associated with the hyper-connectivity. Group 3 mGluRs act by inhibiting the cyclic AMP pathway, which normally activates the Protein Kinase A (PKA) enzyme. PKA phosphorylation of the 2B NMDA receptor subunit is excessive and thus activating the group 3 receptor prevents this phosphorylation and reduces the NMDA mediated current.
As used herein, "second messengers" are molecules that relay signals received at receptors on the cell surface such as the arrival of protein hormones, growth factors, etc. to target molecules in the cytosol and/or nucleus. There are 3 major classes of second messengers: cyclic nucleotides {e.g., cAMP and cGMP), inositol trisphosphate (IP3) and diacylglycerol (DAG) and calcium ions (Ca2+). Preferably, the second messenger of the present invention is the Ca2+ ion. Calcium ions are important intracellular messengers since they are probably the most widely used intracellular messengers. The applicants have evidence for an increase in current triggered by NMDA receptors. Some of this current may be a high voltage activated channel that does not inactivate. Such channels are typically from the L and N type calcium channel
classes. In response to many different signals, a rise in the concentration of Ca2+ in the cytosol triggers many types of events such as e.g. release of neurotransmitters at synapses (and essential for the long-term synaptic changes that produce Long-Term Potentiation (LTP) and Long-Term Depression (LTD). Therefore, encompassed by the present invention is also an intracellular Ca2+ levels blocker or reducer such as Acetoxymethyl (AM) or Acetate Esther versions of buffers, intracellular calcium release blockers, gene therapeutic agents that induce enhanced expression of calcium buffers, Signal Transduction Agents (e.g. CaM kinase II inhibitors, CaM kinase IV inhibitors, Myosin light chain kinase inhibitors), Calcium Signalling Agents, Calcium Binding Protein Modulators (e.g. Calmodulin antagonists), agents blocking the phosphorylation of subunit NR2B, CREB, GIuRl on residue Ser 831 (a protein required for trafficking of AMPA receptors) , or ERK 1 or 2.
Also encompassed by the present invention is a composition capable of reducing memory, perception and/or attention by reducing intracellular calcium changes comprising a drug selected from the groups comprising the NMDA receptor antagonists, the non-inactivating Calcium channels antagonists, the blockers of intracellular calcium release, a blocker of the metabotropic receptor class of neurotransmitters that are linked to the intracellular release of calcium such as, for example, the metabotropic glutamate receptors from group I, and/or a combination thereof. The present invention also envisioned a composition capable of reducing memory, perception and/or attention by preventing release of calcium from intracellular stores by blocking the activation of alpha 1 adrenergic receptors, said composition comprises a drug selected from the group comprising a noradrenergic receptor antagonist, a noradrenergic uptake enhancer, and/or a combination thereof.
Exemplary calcium channel blockers comprise, but are not limited to: Ca2+ channel blocker fL-type)
Nimodipine (l,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2- methyloxyethyl 1-methylethyl ester),
Nitrendipine (l,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-ρyridine dicarboxylic acid ethyl methyl ester), Verapamil hydrochloride (α-[3-[[2-(3,4-Dimethoxyphenyl)ethyl]methylamino]propyl]-3,4- dimethoxy- α -(l-methylethyl)benzeneacetonitrile hydrochloride),
Diltiazem hydrochloride (2S-cis)-3-(Acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2- (4-methoxyphenyl)- 1 ,5-benzothiazepin-4(5H)-one hydrochloride),
Gabapentin (l-(Aminomethyl)cyclohexaneacetic acid),
Nifedipine (l,4-Dihydro-2,6-dimethyl-4-(2-nitroρhenyl)-3,5-ρyridinedicarboxylic acid dimethyl ester),
(S)-(+)-Niguldipine hydrochloride ((S)-l,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5- pyridinedicarboxylic acid, 3-(4,4-diphenyl-l-piρeridinyl)propyl methyl ester hydrochloride),
(R)-(+)-Bay K 8644 ((4R)- 1 ^-Dihydro^^-dimethyl-S-nitro^-tl-trifluoromethyOphenylJ-S- pyridinecarboxylic acid methyl ester),
SR 33805 (oxalate 3,4-Dimethoxy-N-methyl-N-[3-[4-[[l-methyl-3-(l-methylethyl)-lH- indol-2-yl]sulfonyl]ρhenoxy]propyl]benzeneethanamine oxalate), Potent Ca2+ channel antagonist; binds allosterically to the ai-subunit ofL-type Ca2+ channels (Kd = 2OpM), at a site distinct from other types of blocker.
Isradipine (4-(2, 1 ,3 -Benzoxadiazol-4-yl)- 1 ,4-dihydro-2,6-dimethyl-3 ,5-pyridinecarboxylic acid methyl 1-methylethyl ester),
Ca2+ channel blocker (TST, P and O-type) ω-Conotoxin MVIIC, ω-Conotoxin GVIA, Ziconotide
(R)-(-)-Niguldipine hydrochloride ((R)- 1 ,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5- pyridinedicarboxylic acid), 3-(4,4-diphenyl-l-piρeridinyl)propyl methyl ester hydrochloride,
SKF 96365 (hydrochloride l-[2-(4-Methoxyphenyl)-2-[3-(4-methoxyphenyl)propoxy]ethyl- lH-imidazole hydrochloride),
Ruthenium Red (Ammoniated ruthenium oxychloride).
L-T ype calcium channel blockers, such as those from the dihydropyridine, phenylalkylamines and benzothiazepine chemical classes.
Amlodipine (Norvasc™, Lotrel™),
Felodipine (Plendil™, Lexxel™),
Isradipine (Dynacirc™),
Nicardipine (Cardene™), Nifedipine (Adalat™, Procardia™),
Nimodipine (Nimotop ™),
Nisoldipine (Sular™),
Verapamil (Isoptin™), Diltiazem (Angizem, Altiazem), Bepridil (Vascor™).
Blockers of Intracellular Calcium Release
Blockers of ryanodine receptors (RyRs) and inositol l,4,5-(-trisphosphate receptors (IP3Rs),
Alphal -adrenergic receptor blockers,
Ryanodine which blocks the Ryanodine receptor and blocks intracellular calcium release.
Usually, the therapeutically effective amount of a composition of the present invention capable of reducing memory, perception and/or attention by enhancing synaptic weakening includes also a drug selected from the group comprising a metabotropic glutamatergic receptor (mGluR) antagonist, a CREB gene down regulator, a CREB phosphorylation blocker and/or a combination thereof.
Applicants have shown that when the group 1 metabotropic receptors, and more specifically the mGluR5 receptor is blocked, TD is prevented. It is known that mGluR5 triggers a signaling pathway called the Inositol Phosphate Pathway. This pathway is a controlled by Ca2+ influx into neurons which occurs during electrical activity and attenuating this pathway is therefore also a potential target for treating autism.
In case the drug is a metabotropic glutamatergic receptor (mGluR) antagonist, then preferably the metabotropic glutamatergic receptor (mGluR) antagonists are mGluR Group I antagonists. Preferably, mGluR Group I antagonists will selectively target the neocortex, most preferably by differential affinities of the antagonists. For example, mGluR5, a member of the niGluR Group I, triggers a signaling pathway called the Inositol Phosphate Pathway. This pathway is a controlled by Ca2+ influx into neurons which occurs during electrical activity and attenuating this pathway is therefore also useful for reducing memory, perception and/or attention by enhancing synaptic weakening. Exemplary mGluR Group I antagonists comprise, but are not limited to:
DL-AP3 (DL-2-Amino-3-phosphonopropionic acid),
(S)-4-Carboxy-3-hydroxyphenylglycine, (S)-4-Carboxyphenylglycine (S)-3-Carboxy-4-hydroxyphenylglycine (RS)-MCPG ((RS)- α -Methyl-4-carboxyphenylglycine),
(S)-MCPG ((S)-a-Methyl-4-carboxyphenylglycine),
ADDA ((RS)-l-Aminoindan-l,5-dicarboxylic acid),
E4CPG ((RS)-α-Ethyl-4-carboxyphenylglycine),
PHCCC (N-Phenyl-7-(hydroxyimino)cyclopropa[b]chromen-la-carboxamide ), (IC50 - 3 mM)
CPCCOEt (7-(Hydroxyiniino)cyclopropa[b]chromen-la-carboxylate ethyl ester), (IC50 = 6.5 mM)
SIB 1893 (2-Methyl-6-(2-ρhenylethenyl)pyridine), IQo = 0.3 mM at HmGIu5,
SIB 1757 (6-Methyl-2-(ρhenylazo)-3-ρyridinol), 0.4 mM at HmGIu5
LY 367385 ((S)-(+)-α-Amino-4-carboxy-2-methylbenzeneacetic acid ),
IC5O = 8.8 mMfor blockade of quisqualate-induced phosphoinositide hydrolysis vs. > 100 mMfor mGlu5a
MPEP hydrochloride (2-Methyl-6-(phenylethynyl)pyridine hydrochloride), IC5O = 36 nM at the mGlu5 receptor
HexylHIBO (α-Amino-4-hexyl-2,3-dihydro-3-oxo-5-isoxazolepropanoic acid),
Kb values are 140 and 110 mM at mGlu]a and mGlu5a receptors respectively.
(S)-HexylHIBO ((αS)-α-Amino-4-hexyl-2,3-dihydro-3-oxo-5-isoxazolepropanoic acid), Kb values are 30 and 61 mMat mGluja and mGlu5a receptors respectively
MATIDA (α-Amino-5-carboxy-3-methyl-2-thioplieneacetic acid 3-),
IC50 = 6.3 mMat rat mGluia). Displays ≥ 40-fold selectivity over other receptors: mGlus, mGlu2, mGlu4a (IC50 > 300 niM), NMDA and AMPA (IC50 = 250 niM).
ACDPP hydrochloride (3-Amino-6-chloro-5-dimethylamino-N-2- pyridinylpyrazinecarboxamide hydrochloride),
Antagonist at the mGlu5 receptor (Kt = 295 nM). Inhibits human mGlu5 receptor-mediated calcium flux with an IC50 of 134 nM
Since it has been shown that CREB (Cyclic-AMP Response Element Binding) proteins in neurons are involved in the formation of long-term memories and that they are necessary for the late stage of long term potentiation (LTP) the present invention also envisioned either to down regulate the CREB gene or to block the phosphorylation CREB protein. Down regulating the CREB gene could, for example, occur by using gene regulating mechanisms that limits the transcript level by either suppressing transcription of CREB gene (transcriptional gene silencing), by activating a sequence-specific RNA degradation process (posttranscriptional gene silencing i.e. PTGS/RNA interference), by activating the CREM gene or by the phosphorylation of CREB such as for example on residue 142 or 123.
Usually, the therapeutically effective amount of a composition of the present invention capable of reducing memory, perception and/or attention by reducing synapse formation comprises a drug selected from the group comprising a NCAM expression inhibitor, a synaptophysin expression inhibitor, a cell-to-cell protein expression inhibitor, a receptor recycling inhibitor, and/or a combination thereof.
Cell-to-cell proteins can be selected from the group comprising ephrins, cadherins and cathenins.
Also encompassed in the present invention is a therapeutically effective amount of a composition capable of reducing memory, perception and/or attention by enhancing synaptic breakdown that comprises a drug selected from the group comprising a NOGO expression
enhancer, a blocker that prevents the binding of polysialic acid (PSA) to NCAMs such as endoneurarainidase-N (endo-N), and/or a combination thereof.
Also encompassed in the present invention is a therapeutically effective amount of a composition capable of reducing memory, perception and/or attention by reducing network excitability that comprises a drug that inhibits potassium or calcium channels.
The neurons in autistic animals display a damped down excitability. This is due to the over expression of a variety of potassium channels.
Preferably, said drag will act by blocking the SK2 calcium sensitive potassium channels, or by blocking the BK Ca sensitive potassium channel, or by blocking voltage-gated postassium channels such as the ion channel encoded by the Kv 3.2 and/or the Kv4 beta gene gene, or by blocking L, N, P and/or Q -type calcium channels.
Also encompassed in the present invention is a therapeutically effective amount of a composition capable of reducing memory, perception and/or attention by increasing the level of network inhibition comprises a drag selected from the group comprising a cannabinoid receptor 1 inhibitor, a gamrna-amino butyric acid A (GABA-A) agonist or attenuator, a gamma-amino butyric acid B (GABA-B) agonist or attenuator and/or a combination thereof. In case the gamma-amino butyric acid A (GABA-A) agonist is a GABA-A agonist or attenuator then it is selected from the benzodiazepine groups.
In case the GABA-B inhibitor is a GABA-B agonist, then it is selected from the group comprising, but not limited to:
4-Amino-3-(4-chlorophenyl)butanoic acid ((RS)-Baclofen),
(R)-4-Amino-3-(4-chlorophenyl)butanoic acid ((R)-Baclofen),
CGP 35024 ,
CGP44532,
3-Aminopropyl(methyl)phosphinic acid (SKF 97541).
"Cannabinoid receptor 1" or CBl are found primarily in the brain, specifically in the basal ganglia and in the limbic system, including the hippocampus. They are also found in the cerebellum and in both male and female reproductive systems. CBl receptors appear to be responsible for the euphoric and anticonvulsive effects of cannabis. This receptor has also been implicated in anxiety.
Gene expression analysis indicates that there is an increased expression of the cannabinoid receptor 1, suggesting that autistics are able to "self-administer" anxiety reducing behavior. Inhibition of the cannabinoid receptor 1 will therefore encourage external reward seeking behavior.
Also encompassed in the present invention is a therapeutically effective amount of a composition capable of reducing memory, perception and/or attention by reducing the supply of dopamine to the neocortex that comprises a drug selected from the group comprising a dopamine receptor inhibitor, a dopamine uptake enhancer, and/or a combination thereof. The hyper-connectivity found by the Applicants and the resistance to unlearning new associations suggest that the attentional mechanisms are too strong in Autism. Dopamine is a neurotransmitter that enhances attention in attention deficit disorders and it is therefore desirable to provide the inverse therapy in autism, namely to block dopamine effects.
Applicants have also shown an increase in the somatostatin receptor 2 by Gene expression analysis. This receptor is activated by the release of the neuropeptide somatostatin from a special type of inhibitory neuron called a Martinotti cell. The Martinotti cell is crucial for maintaining electrical balance in the neocortex and imbalance could also account for the high tendency towards seizures and epilepsy in autism. An increase in the expression of the receptor indicates that these interneurons can exert a stronger inhibitory effect, which appears to be a compensatory effect to prevent hyper-excitability. Blocking this receptor in combination could force the hyper-connectivity in reverse. Therefore, also encompassed in the present invention is a therapeutically effective amount of a composition capable of reducing memory, perception and/or attention by blocking the somatostatin receptor 2 that comprises a drug selected from the group comprising neuropeptide receptor blockers, somatostatin synthesis blockers, and/or a combination thereof.
Preferably, in addition to at least one drug as described herein, the composition may contain one or more pharmaceutically acceptable carriers, such as excipients, carriers and/or auxiliaries which facilitates processing of the active compounds into preparation which can be used pharmaceutically. The composition may contain, for example, 0.1 to 99.5%, more preferably 0.5 to 90%) of the drug.
Acceptable carriers, excipients, or stabilizers are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl orbenzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g. Zn-protein complexes); and/or non-ionic surfactants such as TWEEN®, PLURONICS® or polyethylene glycol (PEG).
The form of administration of the composition maybe systemic and/or topical and/or via the nasal cavity. For example, administration of such a composition may be various parenteral routes such as subcutaneous, intravenous, intradermal, intramuscular, intraperitoneal, intranasal, transdermal, buccal routes or via an implanted device, and may also be delivered by peristaltic means.
The composition comprising a drug, as described herein, as an active agent may also be incorporated or impregnated into a bioabsorbable matrix, with the matrix being administered in the form of a suspension of matrix, a gel or a solid support. In addition the matrix may be comprised of a biopolymer.
Sustained-release preparations maybe prepared. Suitable examples of sustained- release preparations include semi permeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g. films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for
example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and [gamma] ethyl-L-glutamate, non- degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT(TM) (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid.
The formulations to be used for in vivo administration must be sterile. This is readily accomplished for example by filtration through sterile filtration membranes.
It is understood that the suitable dosage of the composition of the present invention will be dependent upon the age, sex, health, and weight of the recipient, kind of concurrent treatment, if any and the nature of the effect desired.
The appropriate dosage form will depend on the disease, the drug, and the mode of administration; possibilities include tablets, capsules, lozenges, dental pastes, suppositories, inhalants, nasal inhalers, solutions, ointments and parenteral depots. The selected dosage level will depend upon a variety of factors including the activity of the particular compound, or combination of compound, of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular reuptake inhibitors employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
A physician having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
In general, a suitable daily dose of a composition of the invention will be that amount of the composition which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. Generally, intravenous, intracerebroventricular and subcutaneous doses of the composition of this invention for a patient will range from about 0.0001 to about 100 mg per kilogram of body weight per day.
If desired, the effective daily dose of the composition may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.
In case the composition of the invention are associated with an antidepressant drug such as selective serotonin-reuptake inhibitors (SSRIs), an anticonvulsive drug, or an antipsychotic drug, or and combinations thereof, the dosage level may vary accordingly.
It is also understood that the described method not only applies to autistic children or autistic adults but also to pregnant non-autistic women in order to prevent the appearance of autistic conditions in the fetus, hi such a case, the therapeutically effective amount of a composition capable of reducing memory, perception and/or attention according to the present invention will be administered as soon as a diagnosis is possible. It is not currently possible to diagnose an autistic fetus, but a gene expression screen of amitotic fluid may reveal the changes found in autism. Treatment must start as early as possible to prevent the formation and consolidation of this disorder during development.
Preferably, treatment will start within the first three years of the children, but because plasticity of the circuitry continues well beyond adulthood, the prescribed treatment regime can be administered effectively at any age.
Also encompassed by the present invention is the use of a composition of the invention in the preparation of a medicament for treating and/or preventing a Pervasive Developmental Disorder.
It is another embodiment of the invention to provide a kit for treating and/or preventing a Pervasive Developmental Disorder in a subject in need thereof, said kit comprising a therapeutically effective amount of a composition of the present invention capable of reducing memory, perception and/or, optionally with reagents and/or instructions for use.
The kit of the present invention may further comprise a separate pharmaceutical dosage form comprising an antidepressant drug such as selective serotoriin-reuptake inhibitors (SSRIs), an anticonvulsive drug, or an antipsychotic drug, and combinations thereof.
Generally, the Kit comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, etc. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is effective for treating the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). At least one active agent is a composition of the present invention. The label or package insert indicates that the composition is used treating and/or preventing a Pervasive Developmental Disorder, such as autism.
Alternatively, or additionally, the Kit may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.
Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications without departing from the spirit or essential characteristics thereof. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations or any two or more of said steps or features. The present disclosure is therefore to be considered as in all aspects illustrated and not restrictive, the scope of the invention being indicated by the appended Claims, and all changes which come within the meaning and range of equivalency are intended to be embraced therein.
Various references are cited throughout this Specification, each of which is incorporated herein by reference in its entirety.
The foregoing description will be more fully understood with reference to the following Examples. Such Examples, are, however, exemplary of methods of practising the present invention and are not intended to limit the scope of the invention.
EXAMPLES
Electrophysiology
The valproic acid rat model of autism
Wistar Han rats (Charles River Laboratories, L'Arbresle, France) were mated, with pregnancy determined by the presence of a vaginal plug on embryonic day 1 (El). The sodium salt of valproic acid (NaVPA, Sigma) was dissolved in 0.9% saline for a concentration of 150 mg/ml, pH 7.3. The dosing volume was 3.3 ml/kg, the dosage was adjusted according to the body weight of the animal on the day of injection. Treated rats received a single ip injection of 500 mg/kg NaVPA on gestation day GD 12.5, control rats were untreated [I]. Delivery of this dose to rats during embryogeneis has been shown to result in maximum levels of total valproic acid in maternal plasma in less than 1 hour, with a mean plasma elimination half life of 2.3 h [2].
Dams were housed individually and were allowed to raise their own litters. The offsprings were used for experiments on postnatal day 12 to 16 (PN12-PN16).
Acute slice preparation
All experimental procedures were carried out according to the Swiss federation rules for animal experiments. Offspring (PN12 to PN16) were rapidly decapitated and sagittal neocortical slices (300 μm) were sectioned on a vibratome (HR2, Sigmann Elektronik) filled with iced extracellular solution. Optimal slices, running parallel to the apical dendrites of pyramidal cells, were selected for recording. Slices were incubated for 30 minutes at 350C and then at room temperature until transferred to the recording chamber (room temperature or 340C). The extracellular solution contained (niM): 125 NaCl, 2.5 KCl5 25 glucose, 25
NaHCO3, 1.25 NaH2PO4, 2 CaCl2 and 1 MgCl2. Neurones in somatosensory cortex were identified using IR-DIC microscopy, with an upright microscope (Olympus Bx51Wl, fitted with a 60x/0.90 W objective, Olympus, Switzerland). Recorded neurons were selected up to 70 μm below the surface of the slice.
Electrophysiological recording
Simultaneous whole-cell recordings from clusters of up to four neurons (pipette resistance 4 to
10 MΩ) were made and signals were amplified using Axopatch 200B amplifiers (Axon Instruments). Neurones were submitted to different type of protocols depending on what properties were being looked at. Voltages (in I-clamp mode) or current (in V-clamp mode) were recorded with pipettes containing (mM): 100 potassium gluconate, 20 KCl, 4 ATP-Mg, 10 phosphocreatine, 0.3 GTP, 10 Hepes (pH 7.3, 270-300 mOsm) and 0.5% biocytin (Sigma).Membrane potentials were not corrected for the junction potentials between pipette and bath solution ( ~10 mV).
Intrinsic properties of the cells:
During whole-cell patch-clamping, neurones were submitted to a series of somatic current injection designed to capture their key active and passive electrical properties. Recordings were sampled at intervals of 10-400 μs using Igor (Wavemetrics, Lake Oswego, OR, USA), digitized by an ITC- 18 interface (Instrutech, Great neck, NY, USA) and stored for off-line analysis. The results were calculated as a mean of 89 cells from control rats and 100 cells from NaVPA treated rats. Connectivity: Synaptic direct connections were examined by eliciting short trains (8 pulses) of precisely timed action potentials (APs) at different frequencies (20 to 70 Hz) followed by a recovery test response 500 ms later. The average synaptic response to this stimulation protocol allows the extraction of the basic parameters of the synaptic connection with a model of dynamic synaptic transmission (Ase, the absolute strength of the connection; U, equivalent to average P; d, the time constant to recover from depression) [3] The number of analyzed connections was 41 for control slices, 33 for treated slices.
For the observation of disynaptic connectivity, neighboring thick tufted layer V pyramidal cells (PCs) were recorded and stimulated with high frequency action potential (AP) trains (15
regular pulses at 70Hz). When the cells were connected via an intermediate interneuron, inhibitory responses were observed on neighboring PCs. The amplitude, latency and half- width of these responses were approximated with a Gaussian fit (control cells: n = 275, treated cells: n = 208 polysynaptic connections).
Long term potentiation :
To check long term potentiation, a connection was, five minutes after a testing period (same protocol as described above ), stimulated with a pairing protocol consisting of Poisson train stimulation of high frequency (50Hz) to the postsynaptic cell and of low frequency (5Hz) to the presynaptic cell, for 30 seconds. The connection was tested after two Poisson pairing sessions, each 15 minute for 30 minutes (control connections: n = 15, treated connections: n = 13).
MEA stimulation: Multi-site extracellular stimulations were performed using a multi-electrode array (MEA) made of 60 3D Pt electrodes (Ayanda Biosystems, EPFL, Switzerland), on top of which acute brain slices were glued with a solution of nitrocellulose (0.14 mg/ml in ethanol). The responses of these stimulations were recorded in whole-cell patched layer 2/3 pyramidal cells. For the study of cell response with minimal network stimulation, 8 different MEA electrodes were stimulated non- simultaneously (single pulse of 0.5 to 1. IV) and current were recorded in V-clamped cells (holding voltage between -80 and -4OmV). Total synaptic, excitatory and inhibitory conductances could then be calculated according to the method described in [4]. 38 control cells (n = 420 inputs) and 49 treated cells (n = 480 inputs) were used for the analysis. For the study of strong network stimulation, 16 MEA electrodes were stimulated simultaneously with a Poisson train (50Hz, 300 ms) at increasing stimulation amplitude
(normalized to the response amplitude). Whole-cell V-clamped cells filled with Qx-314 were then recorded at -80, -57 and +10 mV to get the contribution of respectively all synaptic components, of inhibitory components and excitatory components. 12 control and 12 treated cells were kept for the analysis.
Pharmacological compounds;
N-Methyl-D-aspartate receptors (NMDARs) were blocked using 20 μM D-2-amino-5- phosphonopentanoic acid (D-APV, Sigma). L-amino-3-hydroxy-5-methyl-4- isoxazolepropionate receptors (AMPARs) were blocked using 10 μM 6-cyano-7- nitroquinoxaline-2,3-dione (CNQX disodium salt, Sigma), μ-aminobutyric acid A receptors (GABAARS) were blocked using 20 μM bicuculline (Sigma).γ-aminobutyric acid B receptors (GABABRS) were blocked using 100 μM CPG-35348 (Tocris). Lidocaine n-ethylbromide quaternary salt (QX-314, 5 μM, Sigma) was used to block voltage-gated channels.
Histological procedures and 3-D reconstruction After recording, slices were fixed for 24h in cold 0.1M phosphate buffer (PB, pH 7.4) containing 2% paraformaldehyde and 0.3% saturated picric acid. Thereafter, slices were rinced several times in PB, and transferred in phosphate buffer 3% H2O2 for 30 min to block endogeneous peroxidases. They were then incubated overnight at 4°C in biotinylated horseradish peroxidase conjugated to avidin according to the manufacturer's protocol (ABC- Elite, Vector Laboratories, Peterboroug, UK). Following incubation, sections were washed several times in PB and developed with diaminobenzidine under visual control. The reaction was stopped by transferring the slices into PB. After washing in the same buffer, slices were mounted in aqueous mounting medium (IMMCO Diagnostics, hie).
3-D neurone models were reconstructed from five control and five treated stained cells using Neurolucida system (MicroBrightField Inc., USA) and a bright-field microscope (Olympus).
1. Ingram, J.L., et al., Prenatal exposure of rats to valproic acid reproduces the cerebellar anomalies associated with autism. Neurotoxicol Teratol, 2000. 22(3): p.
319-24.
2. Binkerd, P.E., et al., Evaluation of valproic acid (VPA) developmental toxicity and pharmacokinetics in Sprague-Dawley rats, Fundam Appl Toxicol, 1988. 11(3): p. 485- 93. 3. Markram, H., Y. Wang, and M. Tsodyks, Differential signaling via the same axon of neocortical pyramidal neurons. Proc Natl Acad Sci U S A, 1998. 95(9): p. 5323-8.
4. Borg-Graham, LJ., C. Monier, and Y. Fregnac, Visual input evokes transient and strong shunting inhibition in visual cortical neurons. Nature, 1998. 393(6683): p. 369- 73.
Behavioral Testing
Overview
Several lines of behavioural tests were conducted on a total of 120 adolescent (approximately 6 weeks old at the beginning of experiments) and adult (approximately 12 weeks old at the beginning of experiments) on male and female, treated and untreated rats. The testing focused on perception, learning and memory capabilities and involved the following tests: Startle response and pre-pulse inhibition
- Fear conditioning and extinction - Water maze.
Animals
Male and female Wistar rats (own breeding), 6 to 12 weeks old at the beginning of the experiments, were housed in groups of three to five per cage, under light (12 hr light/dark cycle; light on at 7 A.M.)-and temperature (22± 2° C)-controlled conditions. Food and water were available ad libitum. All animals were handled for 5 minutes every day for 3 days preceding the first day of the behavioural tests. Animal care procedures were conducted in accordance with the guidelines set by the European Community Council Directives (86/609/EEC) and Ecole Polytechnique Federate de Lausanne (EPFL), Switzerland.
Startle response and pre-pulse inhibition
The startle apparatus (Columbus Instruments, Ohio) consisted of aplastic, transparent cage, equipped with a movable platform floor attached to a sensor, which recorded vertical movements of the floor. A loudspeaker was suspended above the cage, and it was placed in a soundproof box. A transient force resulting from up-and-down movements of the floor,
evoked by a startle reaction to acoustic stimuli, was recorded by PC using a recording window of 200 ms measured from the onset of the acoustic stimulus. The amplitude of a startle response was defined as a difference between the average force detected within a recording window and the force measured immediately before the stimulus onset. The threshold was set at 20 g and allowed for correct evaluation of the maximum response in all the animals tested.
The experiment started with an adaptation period during which the animals were placed in experimental cages for 5 min and exposed to a 70 dB background white noise. Following habituation, baseline startle responses were recorded by confronting the rats with 5 tone pulses (15 dB, with a random intertrial interval of 10-30 sec). Immediately afterwards a series of prepulse-pulse stimulation was initiated consisting of 12 pulse alone trials, and 4 prepulse- pulse combinations, each made up by 6 trials. The combinations consisted of either a 78 or 86 dB prepulse tone preceding the main pulse by either 30 or 120 ms. Each trial was separated by a random intertrial interval of 10 to 30 sec. The trial order was random. The experiment concluded with a series of 5 pulses alone, the same as during baseline recordings.
Prepulse inhibition was calculated as the percentage of inhibition of the startle amplitude evoked by pulse alone: ((pulse-prepulse)/pulse) x 100.
Fear conditioning
Training and testing took place in a rodent observation cage (30 x 37x 25 cm) that was placed in a sound-attenuating chamber. The side walls of the observation cage were constructed of stainless steel, and the door of Plexiglas. The floor consisted of 20 steel rods through which a scrambled shock from a shock generator (model LI 100-26 Shocker, LETICA LC, Madrid, Spain) could be delivered. Each observation cage was cleaned with a 0.1% acetic acid solution before and after each session. Ventilation fans provided a background noise of 68 dB, and a 2OW white light-bulb illuminated the chamber.
On the training day for auditory fear conditioning rats were exposed to a conditioning chamber during 160 sec, followed by three presentations of a tone-shock pairing in which the tone (20 sec, 85dB sound at 1000Hz) co-terminated with a footshock (1 mA, 1 sec). The inter-tone interval was 40 sec and the conditioning session lasted 5.5 min. On the next day, the animals
were re-exposed to the context in which they originally received the tone-footshock pairings but in the absence of tones and shocks. One day after the context test, the rats were put in a novel context for 8 min in which they were re-exposed to the tone, but not the shocks, continuously during the last 5 minutes of the test (tone test). Remote memories for both, context and tone, were re-assessed one and again two months after fear-conditioning.
Subsequently, rats were re-conditioned to the tone (0.5 mA, 1 sec) in order to re-establish the fear memory and underwent a two-day extinction procedure consisting of a 30 min protocol per day, in which 20 sec tone intervals alternated with 40 sec no-tone intervals. Over the two days, rats were exposed to 60 tone stimulations in total. One day and one month after extinction training animals were re-tested for their tone memory using the same protocol as in the previous tone tests.
Using a time-sampling procedure every 2 sec, each rat was scored blindly as either freezing or active. Freezing was defined as behavioural immobility except for movement needed for respiration.
Water maze
Training and testing took place in a black, circular water tank (170 cm in diameter, 50 cm high, custom-made in the house) surrounded by grey curtains containing several spatial cues (e.g. plastic flowers, geometrical patterns, poster or clothes attached to the curtains and walls). The water temperature was 25° C +/- 1 ° C.
For the spatial training task, a 12 cm in diameter escape platform was placed with the top surface 1.5 - 2.5 cm below the water level at one of four positions in the pool. Each trial was initiated by placing the animal in one of four randomly chosen locations near the wall of the tank. Animals were allowed to search for the hidden platform for a maximum of 90 sec. If an animal reached the platform before the maximum time, the trial was stopped. In case the animal did not find the platform during this time, it was guided by the experimenter towards it and in both cases it was left on the platform for further 30 sec. Each learning day consisted of four consecutive learning trials, with 30 sec intertrial intervals. In total a session would last maximally 8 min. At the end of a learning session the animal was dried and taken to a recovery cage placed under a red light and subsequently returned to its home cage. Training
consisted of a total of four learning sessions. One day and approximately three weeks later, spatial memory was tested in probe trials by removing the platform from the pool and placing the animal for 90 sec into the pool. After the second probe trial animals received two more learning sessions on consecutive days in order to re-establish a strong spatial memory. The following day, the platform was changed to the opposite position and rats underwent a final reversal learning session, the protocol being the same as above.
Learning was assessed as the latency to reach the platform. Memory performance was estimated by means of variables such as time spent, distance moved in the target quadrant as opposed to the opposite quadrant and the frequency of platform position crossing. All behaviour and learning and memory variables were registered by means of a video tracking system (Etho vision, Noldus).
Statistical analysis All results were expressed as mean ± SEM and analyzed using repeated measure ANOVA or one-way ANOVA where appropriate. Differences between different conditions were further evaluated for significance with Tukey's post hoc test. In all cases significance of results was accepted at p <0.05.
Genomics
Single cell cytoplasm harvesting using Patch-Clamp electrodes, RNA isolation/amplification and gene expression quantification (Q-PCR and/or oligonucleotide microarrays)
All experimental procedures were carried out according to the Swiss federation guidelines for animal experiments. Wistar rats (13-16 days old) were rapidly decapitated and neocortical slices (sagittal; 300 mm thick) were sectioned on a vibratome (DSK, Microslicer, Japan) filled with iced extracellular (mM): 125 NaCl, 2.5 KCl, 25 glucose, 25 NaHCO3, 1.25 NaH2PO4, 2 CaCl2, and 1 MgCl2. Neurones were identified using IR-DIC microscopy as previously described. Somatic whole-cell recordings of layer 5 pyramidal cells (pipette resistance-3 MΩ) were employed for harvesting their cytoplasmic contents. Pipettes were filled with RNase free intracellular solution, containing (mM) 100 potassium gluconate, 20 KCl, 4 ATP-Mg, 10 phosphocreatine, 0.3 GTP and 10 Hepes (pH 7.3, 310 mOsmol, adjusted with sucrose). The
intracellular solution was prepared under RNAse free conditions: water was autoclaved; glassware and pH meter were cleaned with NaOH (10N) and chemicals were opened from the first time using gloves and RNAse free tools. After preparation, the intracellular solution was tested for RNAse contamination. Right after whole cell configuration, cell cytoplasm was aspirated into the recording pipette under visual control by applying gentle negative pressure. Only cells in which the seal was intact throughout the recording, and whose nucleus was not harvested, were further processed. The electrode was then withdrawn from the cell to form an outside-out patch that prevented contamination as the pipette was removed. The tip of the pipette was broken and the contents of the pipette expelled into a test tube by applying positive pressure. The contents of cells harvested from the same animal where pooled at the end of the day and the RNA was cleaned and isolated using silica-gel-membrane columns (RNeasy Micro Kit, Qiagen) and stored at -800C before further processing.
RNA messenger was reverse transcribed using an oligo-dT and linearly amplified using a two round amplification kit (Epicenter) The quality of the amplified RNA was controlled on a Nano LabCbip (Agilent Technologies) and samples with high quality aRNA were either a) labeled and hybridize on oligonucleotide microarrays (Agilent and/or Affymetrix); or b) tested for the quantitative expression of selected genes using real time PCR (Applied Biosystems).
Laser capture microscopy (LCM), RNA isolation/amplification and gene expression quantification (Q-PCR and/or oligonucleotide microarrays)
AU experimental procedures were carried out according to the Swiss federation guidelines for animal experiments. Wistar rats (14 days old) were rapidly decapitated and their brains (entire or one hemisphere) were immediately frozen in 2-methylbutane-dry ice mix, and stored at - 800C.
Coronal 8-12 um sections were cut on a cryostat and thaw mounted on PEN-membrane coated or non-coated glass slides. Sections were stained with brief Nissl stain for neuronal identification: 70% ethanol 1 min, water 5 dips, 1% cresyl violet 20 s, water 5 dips, processing through graded ethanols 70/95/100% (30 s each) and xylene 5 min. Neurons were captured using two LCM systems: AutoPix LCM system (Arcturus) and PALM MicroLaser System (P.A.L.M. Microlaser Technologies):
Laser capture microdisection using the AutoPix LCM system (Arcturus). After Nissl staining, layer 5 pyramidal cells (somatosensory cortex and prefrontal cortex) were dissected using the AutoPix LCM system (Arcturus), adjusting the voltage and duration of the laser beam to allow capture of neuronal cytoplasm without adjacent tissue. The captured cells were collected onto CapSureTM HS caps covered with a thermoplastic film. The harvested cells were solubilized from the film in extraction buffer provided in the Arcturus Pico PureTM RNA isolation kit for 30 min at 400C and stored at -800C.
Laser capture microdisection using the PALM® MicroLaser System (P.A.L.M. Microlaser Technologies).
Right after Nissl staining, layer 5 pyramidal cells (somatosensory cortex and prefrontal cortex) on polyethylene naphthalate membrane coated slices were dissected using the PALM MicroLaser System (P.A.L.M. Microlaser Technologies). The captured cells were collected onto PALM AdhesiveCaps. The harvested cells were solubilized in extraction buffer provided in the RNeasy Micro Kit, Qiagen and stored at -8O0C.
At the end of each microdisection section part of the remaining brain slices was scraped from the glass slides and the RNA was isolated. All procedures were done under RNAsefree conditions.
Before amplification the quality of the scraped brain controls was controlled by detecting 18S and 28S bands on RNA 600 Nano LabChip (Agilent Technologies). The captured material (pooled of single neurons) was DNAse I treated and the RNA was purified using silica-gel- membrane columns (Pico PureTM RNA isolation kit, Arcturus or RNeasy Micro Kit, Qiagen) We performed double round amplification of the isolated mRNA with the RiboAmp RNA amplification kit, according to manufacturer's instructions (Arcturus). The quality of the amplified RNA was controlled on a Nano LabChip (Agilent Technologies) and samples with high quality aRNA were either a) labeled and hybridize on oligonucleotide microarrays (Agilent and/or Affyrnetrix); or b) tested for the quantitative expression of selected genes using real time PCR (Applied Biosystems).
Data analysis
Oligonucleotide microarrays (Agilent and Asymetrix) were analyzed (probe level data preprocessing, quality checks, normalization, and visualization) using the RACE (Remote Analysis Computation for gene Expression data suite), a collection of web tools designed to assist with the analysis of DNA microarray data and results.
Immunoblotting
Preparation of brain membrane extracts
Rat brains were homogenized in 8 volumes of cold homogenization buffer A (0.32M sucrose, 1OmM HEPES/KOH, and the following protease inhibitors 0.3mM PMSF, 0.7μg/ml Pepstatin, 2μg/ml Aprotinin, 2μg/ml Leupeptin) using a motor driven glass-teflon homogenizer. The homogenate was spun at 450Og in a Beckman centrifuge to remove the pelleted nuclear fraction, the supernatant was spun at lOOOOOg for 40min. in a Beckman ultracentrifuge. The pellet was resuspended in buffer B (20 niM HEPES/KOH pH7.4, 2 mM EDTA, 2 mM EGTA, 0.1 mM DTT) containing 0.1 M KCl, 0.3mM PMSF, 0.7μg/ml
Pepstatin, 2μg/ml Aprotinin, 2μg/ml Leupeptin. The suspension was rehomogenized using a glass-teflon homogenizer and spun at lOOOOOg for 40min. Membrane pellets were lysed in buffer B (20 mM HEPES/KOH pH7.4, 2 mM EDTA, 2 mM EGTA, 0.1 mM DTT) containing 0.1 M KCl, 1% Triton XlOO, 0.3mM PMSF, OJμg/ml Pepstatin, 2μg/ml Aprotinin, 2μg/ml Leupeptin for 30min. at 40C and spun at 1001OOOg for 40min. 2 g of rat brain was lysed in a volume of 5 ml, yielding a concentration of 8 mg/ml.
Preparation of brain slices
Brain slices of the somatosensory cortex from NaVPA treated and control animals were homogenized in sucrose buffer (0.32M sucrose, 1OmM Hepes protease inhibitors 0.3 mM PMSF, 0.7 μg/ml Pepstatin, 2 μg/ml Aprotinin, 2 μg/ml Leupeptin) at 800rpm with an eppendorf pellet pistel. Triton was added to a final concentration of 1% and the homogenate rolled for 5min. at 4°C. The homogenate was spun 5min. at full speed and 40C. The supernatant was assayed for the protein concentration using a Bradford dosage kit (Biorad) and Lammli buffer 2x (4% SDS, 6OmM Tris pH6.8, 10% glycerol, 5% D-mercaptoethanol) was added. Samples were kept at -20°C.
Preparation of region specific brain extracts
Rats (n=5 males, VPA treated; n=5 males, saline treated) were sacrificed by rapid decapitation. Their brains were extracted and frozen in isopentane (-500C) within 45 sec of decapitation and stored at -80°C until dissection. One-millimeter coronal slices of brain were cut in a cryostat (Leica ) kept at -200C. Tissue punches were obtained from primary somatosensory cortex, secondary somatosensory cortex, and prefrontal cortex, and then sonicated in 1% sodium dodecyl sulfate (SDS). Protein concentrations of the samples were determined using the bichinconinic acid assay (Pierce Chemical Company; Rockford, IL). Sample concentrations were equalized by diluting with 1% SDS and loading buffer 4X (16% glycerol, 8% SDS, 3% Tris, 20% beta-mercaptoethanol, and 0.5% bromophenol blue) to yield a final protein concentration of 1.33 mg/mL.
SDS-Page Electrophoresis
Samples were subjected to SDS-polyacrylamide gel electrophoresis (10% acrylamide/0.27% N, N'-methylenebisacryalamide resolving gel) for 50 min at 185 volts. For each electrophoresis run, increasing amounts of protein pooled from the brain region being tested were run alongside the individual samples and used to produce a standard curve. Proteins were transferred electrophoretically to rmmobilon-P membranes (Millipore Corp; Bedford, MA) at 75 volts for 70 min. Blots were stained with Ponca Red and then rinsed with 0.1 M PBS for 10 min. Membranes were incubated in blocking buffer (Odyssey blocking buffer diluted in 0.1 M PBS) for 1 hour at room temperature. Membranes were then incubated overnight at 4 0C with primary antibody diluted in blocking buffer with 0.1% TweerώO.
After incubation with primary antibodies, blots were rinsed in 0. IM PBS with 0.1 % Tween20 and were processed with fluorescent secondary antibodies (Molecular Probes, Rockland
Chemicals) diluted blocking buffer with 0.1% Tween20. The blots were rinsed in 0.1 M PBS for 1 hour. Fluorescence from the blots was detected by digital scanning in transparency mode using the Odyssey system. Band intensities were quantified using Odyssey software. Band intensities from test samples were compared to the band intensities from the standard curve.
Immunohistochemistry
Rats were deeply anesthetized with pentobarbital (65 mg/200-350 gm). Rats were then perfused transcardially with 50 ml of 0.1 M sodium phosphate with 1.0 niL of heparin (1000 units/mL), pH 7.4 followed by 100 ml of 4% paraformaldehyde in 0.1 M sodium phosphate, pH 7.4. Brains were removed from the skull and post-fixed for 24 hr at 4°C before being transferred to 20% sucrose in 0.1 M sodium phosphate, pH 7.4, for 48 hr at 40C. Brains were frozen in powdered dry ice and stored at -20° C.
Coronal sections (40 μM) were cut in a cryostat, collected in ethylene-glycol cryoprotectant, and stored at -80° C until further processing. To control for variability that might be introduced during immunocytochemical processing, sections for each treatment group were processed at the same time, such that each batch contained tissue from saline treated rats and valproic acid treated rats. The tissue was allowed to come to room temperature for one hour. Sections were rinsed 3 X 3 minutes in tris-buffered saline (TBS) with 0.1% Tween 20 (TBST) and 0.1 % Triton followed by a 20 minute rinse in 0.7% H2O2 diluted in TBST. Sections were rinsed 3 X 3 minutes in TBST and placed in blocking buffer for 1 hr at 220C. The blocking buffer consisted of 10% normal serum in TBST. Sections were incubated overnight at 4°C in primary antibody diluted in 10% normal rabbit serum in TBST. After sections were washed in TBST, they were processed using a standard secondary detection system with ABC and nickel DAB.
Neurons were counted bilaterally at no less than two different anatomic levels for each anatomic structure (medial PFC, primary somatosensory cortex, and secondary somatosensory cortex). Bright-field images of immunoreactive-postive soma were captured using a digital camera and automatically counted using a computerized system.
Results
The Applicants for the first time ever performed experiments to examine the cellular, synaptic and local circuit changes in an animal model of autism as well as novel behavioral
experiments. The applicants also carried out genomic and proteomic studies which reveal the molecules and genes involved in the synaptic, cellular, circuit abnormalities as well as those underlying the behavioral alterations in memory, perception and attention.
Weaker synapses in the Autistic Neocortex
The weak single fiber responses and large response to strong stimulation predicts that the synaptic connections between the excitatory neurons are also weaker in Autism. Applicants therefore recorded from pairs of excitatory pyramidal neurons to study directly the synaptic properties. Indeed, they found that synaptic connections between layer 5 pyramidal neurons were weaker (Figure Ic).
Applicants have shown that when the neocortical microcircuit is stimulated with weak stimulation to activate only one or a few fibers, that lower excitation was produced in the neocortex of autistic animals (Figure Ic).
Increased Total Synaptic Currents in Autistic Neocortex
When Applicants increased the stimulation strengths used to maximally excite the neocortical tissue so that they can study the delivery of synaptic current by the total synaptic pool, Applicants found that much greater excitatory and inhibitory synaptic current is produced by the autistic neocortex (Figure 2). The figure shows a dose-response curve in which the neocortical microcircuit was stimulated in multiple sites at progressively greater stimulus strengths. The response increases to produce a sigmoid response curve. The autistic microcircuit was hyper-excitable in terms of both excitatory and inhibitory voltage as can be seen by the generation of more voltage at lower stimulus strengths and reaching peak responses considerably higher than in control animals (Figure 2). When the traces were normalized to the maximum, the slope was also found to be slightly steeper for the excitation (not shown), indicating that the autistic neocortex is also hyper-reactive to stimuli. When Applicants compared the ratio of excitation to inhibition during the stimulations, they showed that the autistic microcircuit becomes more unbalanced at higher stimulation strengths with excess excitation. These results may explain the hyper-sensitivity to sensory stimulation that is found in the autistic spectrum disorder and the tendency to epilepsy that is found in 38% of autistics.
Hyperconnectivity in the Autistic Neocortex
The weaker individual synapses and higher total current that they can deliver indicates that there are many more synapses formed in the autistic neocortex. Applicants therefore examined this directly by recording from pairs of neurons and determined the probabilities that neurons are connected. Indeed, they found that the probability of forming direct connections between pyramidal neurons nearly doubles (Figure Ia). This is a massive increase since these P to P connections constitute already most of the synapses in the neocortical column (NCC). Applicants also found that the probability to find double synaptic junctions from a pyramidal neuron to an inhibitory neuron and then to a second excitatory neuron was also greatly increased to over 55% (Figure Id). These results provide direct proof that the autistic neocortex is locally hyper-connected. Such local hyperconnectivity also implies that excess synapses are taken by the local connection which would cause a disconnection of the individual neocortical columns from neighbouring columns and distant brain regions. This would lead to self-autonomous modules of neurons in the brain which will be difficult to control by higher brain areas such as attentional mechanisms leaving the autistic "frozen" in its own world. Reducing the local hyper-connectivity will allow long range fibers to enter the columns and restore flexible command of perception, attention and memory.
Increased NMDA-triggered Currents in the Autistic Neocortex.
NMDA receptors are special forms of excitatory transmitter receptors activated by glutamate and are essential for many memory processes. During intense stimulation, synapses are fully activated and it is possible to record the amount of NMDA triggered current that the NCC can produce. The NMDA receptor channel allows the flow OfNa+, K+ and Ca2+ ions. When the cell is held at high potentials then only Ca2+ influx can be detected. Additionally NMDA receptors open neighbouring Calcium channels to allow additional Calcium inflow. Applicants found that the amount of NMDA receptor-mediated current at high potentials is greatly increased in Autism indicating a massive enhancement of Ca2+ ion influx triggered by NMDA receptors (Figure 6). Such Ca2+ influx is known to trigger synaptic learning processes and is important for memory formation. These results therefore suggest that the Autistic neocortex is primed to exaggerated synaptic learning which could lead to hyper-memories.
Protein analysis indicate that the NR2 subunits, NR2A and NR2B, are upregulated (Figure 5), which explains the increased NMDA receptor-induced currents.
Altered synaptic plasticity in the Autstic Neocortex. When two cells are forced to become active together at the same time the synaptic transmission changes. This is known as synaptic plasticity. The applicants found that there is a massive enhancement of a postsynaptic form of plasticity in the autistic (Figure 7). This is most likely due to the increased levels of Calcium into the postsynaptic neuron as found triggered by the NMDA receptors.
Enhanced Fear Memories in Autism
Applicants examined behavioral changes in the autistic model. In addition to the usual behavioral tests for anxiety and social interactions, they performed memory tests which were never performed before on autistics. In particular they wanted to explore fear memories because autistics have enhanced reactions to novel situations that may bee fearful. A link between fear and autism has not previously been reported. Applicants also wanted to determine the degree to which the autistic model retains a memory and how easy it is to reverse a memory. They therefore decided to test behaviorally the memory and memory extinction capabilities in the autistic model. The test they used was classical fear conditioning where a tone is presented followed by an electric shock to the plate on which the rats stand. They found that the Autistic animals remembered the fear memory for much better over a period of 2 months (data not shown). The results are consistent with an increased level of NMDA triggered calcium currents in the Autistic neocortex which suggest that there is more powerful learning and hence they remember events better and for longer. This finding is also consistent with the hyper-connectivity since this would make learning an association much easier because there are more synapses that can be involved.
Impaired Extinction Learning in Autism Applicants then retrained the animals to fully re-instate the memory and began a series of extinction protocols where the tone is given but no shock follows. The results indicate that the
autistics are significantly impaired in their ability to reverse the prior associative conditioning (data not shown).
This suggests that there is a deficit in synaptic depression in autism, which is required to reverse the learning. In addition, the hyper-connectivity may make it easier to remember but more difficult to unlearn prior associations because too many synapses are involved. These experiments indicated that autistics have hyper-memories and that their memories become so fixed that they are unable to re-learn a new association. This could also explain their inflexibility to un-learn previous associations and re-learn new ones that - become relevant and hence their need and demand for extremely structured daily routines. Since many events may require only transient associations to be dropped the next day, this tendency could form the basis of a severe social handicap.
Decreased Pyramidal Neuron Excitability
When Applicants examined the electrical properties of the excitatory neurons they found that the excitability was significantly decreased. In particular, they found that the increase in spiking activity as progressively more current is injected into the neuron, referred to as the current-discharge relationship, was decreased . The maximal discharge when the neurons reach threshold is also greatly depressed. Finally the amount of current required to reach the discharge threshold is significantly increased making it more difficult for the neurons to fire spikes (Figure 3).
These results suggest that the neurons may be trying to compensate for the hyper-excitability caused by the hyper-connectivity by reducing their excitation. These effects could be due to the decreased expression of sodium channels, increased expression of various potassium channels and also result from the increased calcium currents. This is a significant finding since this depressed activity would oppose the hyper-excitable effects of the enhanced connectivity in the microcircuit.
Protein changes in Autism
Applicants carried out a course-grained gene expression analysis in which proteins from somatosensory cortex from controls and autistics were assayed using SDS-page
electrophoresis and immunoblotting. They found a number of protein deficits, but some are particular highly relevant to the hyperconnectictivity disorder. In particular, the subunits 2A and B that are required to build special subtypes of NMDA receptors were up regulated. Another protein alteration is relevant to the hyper-learning disorder: Applicants have shown increased levels of CamKII, a key kinase involved in learning and memory processes, in the treated rats. These results support the excessive learning due to increased intracellular calcium levels (Fig 5).
These protein data further support the results that a major deficit in autism is a hyperconnectivity, excessive learning and memory processes, hand hypo-neuronal excitability in the neurons of the neocortex.
This hyperconnectivity of local microcircuits of neurons may be throughout the brain, but the effects in the neocortex will be devastating for the cardinal cognitive deficits in autism that result from hyper-perception, attention and memory.
Claims
1. A method for treating and/or preventing a Pervasive Developmental Disorder in a subject in need thereof comprising the step of modulating the synaptic connectivity in the neocortex by administering a therapeutically effective amount of a composition capable of reducing memory, perception and/or attention by either i) blocking synaptic strengthening, ii) enhancing synaptic weakening, iii) reducing synapse formation, iv) enhancing synaptic breakdown, v) decreasing network excitability, vi) increasing the level of network inhibition, vii) reducing the supply of dopamine to the neocortex, viii) blocking the somatostatin receptor 2, wherein compositions i) to viii) are administered separately of concurrently.
2. The method of claim 1, wherein the composition capable of reducing memory, perception and/or attention by blocking synaptic strengthening comprises a drug selected from the group comprising a muscarinic receptor antagonist, acetylcholin esterase enhancer, N- methyl-D-aspartate (NMDA) receptor antagonist, second messenger blocker, calcium channel blocker, intracellular calcium blocker, group IH metabotropic glutamatergic receptor agonist (group IH mGluR) and/or a combination thereof.
3. The method of claim 1 , wherein the composition capable of reducing memory, perception and/or attention by enhancing synaptic weakening comprises a drug selected from the group comprising a group I metabotropic glutamatergic receptor (group I mGluIO antagonist, a CamKII gene down regulator, and/or a combination thereof.
4. The method of claim 1, wherein the composition capable of reducing memory, perception and/or attention by reducing synapse formation comprises a drug selected from the group comprising an NCAM expression inhibitor, a synaptophysin expression inhibitor, a cell- to-cell protein expression inhibitor, a receptor recycling inhibitor, and/or a combination thereof.
5. The method of claim 1 , wherein the composition capable of reducing memory, perception and/or attention by enhancing synaptic breakdown comprises a drug selected from the group comprising a NOGO expression enhancer, a PSA-NCAM binding blocker, and/or a combination thereof.
6. The method of claim 1, wherein the composition capable of reducing memory, perception and/or attention by network excitability comprises a drug that inhibits potassium and/or calcium channels.
7. The method of claim 1, wherein the composition capable of reducing memory, perception and/or attention by decreasing the level of network inhibition comprises a drug selected from the group comprising a cannabinoid receptor 1 inhibitor, a gamma-amino butyric acid A (GABA-A) inhibitor, a gamma-amino butyric acid B (GABA-B) inhibitor and/or a combination thereof.
8. The method of claim 1 , wherein the composition capable of reducing memory, perception and/or attention by reducing the supply of dopamine to the neocortex comprises a drug selected from the group comprising a dopamine receptor inhibitor, a dopamine uptake enhancer, and/or a combination thereof.
9. The method of claim 1, wherein the composition capable of reducing memory, perception and/or attention by blocking the somatostatin receptor 2 comprises a drug selected from the group comprising neuropeptide receptor blockers, somatostatin synthesis blockers, and/or a combination thereof.
10. The method of any of the preceding claims, wherein the Pervasive Developmental Disorder is selected from the group comprising Fragile X, autism, mental retardation, schizophrenia and Down's Syndrome.
11. The method of claim 9, wherein the Pervasive Developmental Disorder is autism selected from the group comprising Typical Autism, Atypical Autism/PDD, Autistic Savants, Asperger's Syndrome, and autism associated with Kanner's Syndrome, fragile X, Rett and Down's syndromes.
12. A pharmaceutical composition for treating and/or preventing a Pervasive Developmental Disorder in a subject in need thereof, said pharmaceutical composition being capable of reducing memory, perception and/or attention by either i) blocking synaptic strengthening, ii) enhancing synaptic weakening, iii) reducing synapse formation, iv) enhancing synaptic breakdown, v) decreasing network excitability, vi) increasing the level of network inhibition, vii) reducing the supply of dopamine to the neocortex, viii) blocking the somatostatin receptor 2.
13. The pharmaceutical composition of claim 12 characterized in that it is administered separately or concurrently.
14. The pharmaceutical composition of claims 12 or 13 capable of reducing memory, perception and/or attention by blocking synaptic strengthening, said pharmaceutical composition comprises a drug selected from the group comprising a muscarinic receptor antagonist, acetylcholin esterase enhancer, N-methyl-D-aspartate (NMDA) receptor antagonist, second messenger blocker, calcium channel blocker, intracellular calcium blocker, group III metabotropic glutamatergic receptor agonist (group IE mGluR) and/or a combination thereof.
15. The pharmaceutical composition of claims 12 or 13 capable of reducing memory, perception and/or attention by enhancing synaptic weakening, said pharmaceutical composition comprises a drug selected from the group comprising a group I metabotropic glutamatergic receptor (group I mGluR) antaRonist, a CamKII gene down regulator, and/or a combination thereof.
16. The pharmaceutical composition of claims 12 or 13 capable of reducing memory, perception and/or attention by reducing synapse formation, said pharmaceutical composition comprises a drug selected from the group comprising an NCAM expression inhibitor, a synaptophysin expression inhibitor, a cell-to-cell protein expression inhibitor, a receptor recycling inhibitor, and/or a combination thereof.
17. The pharmaceutical composition of claims 12 or 13 capable of reducing memory, perception and/or attention by enhancing synaptic breakdown, said pharmaceutical composition comprises a drug selected from the group comprising a NOGO expression enhancer, a PSA-NCAM binding blocker, and/or a combination thereof.
18. The pharmaceutical composition of claims 12 or 13 capable of reducing memory, perception and/or attention by network excitability, said pharmaceutical composition comprises a drug that inhibits potassium and/or calcium channels.
19. The pharmaceutical composition of claims 12 or 13 capable of reducing memory, perception and/or attention by decreasing the level of network inhibition, said pharmaceutical composition comprises a drug selected from the group comprising a cannabinoid receptor 1 inhibitor, a gamma-amino butyric acid A (GABA-A) inhibitor, a gamma-amino butyric acid B (GABA-B) inhibitor and/or a combination thereof.
20. The pharmaceutical composition of claims 12 or 13 composition capable of reducing memory, perception and/or attention by reducing the supply of dopamine to the neocortex , said pharmaceutical composition comprises a drug selected from the group comprising a dopamine receptor inhibitor, a dopamine uptake enhancer, and/or a combination thereof.
21. The pharmaceutical composition of claims 12 or 13 capable of reducing memory, perception and/or attention by blocking the somatostatin receptor 2 neocortex, said pharmaceutical comprises a drag selected from the group comprising neuropeptide receptor blockers, somatostatin synthesis blockers, and/or a combination thereof.
22. Use of a composition of claims 12 to 21 in the preparation of a medicament for treating and/or preventing a Pervasive Developmental Disorder.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70343505P | 2005-07-29 | 2005-07-29 | |
US60/703,435 | 2005-07-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007029063A2 true WO2007029063A2 (en) | 2007-03-15 |
WO2007029063A3 WO2007029063A3 (en) | 2007-07-12 |
Family
ID=37836195
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2006/002068 WO2007029063A2 (en) | 2005-07-29 | 2006-07-28 | Treatment and/or prevention of pervasive developmental disorders |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007029063A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008066750A1 (en) * | 2006-11-22 | 2008-06-05 | Seaside Therapeutics, Llc | Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism |
AU2011236093B2 (en) * | 2006-11-22 | 2012-10-18 | Clinical Research Associates, Llc | Methods of treating fragile x syndrome and autism |
EP2948135A4 (en) * | 2013-01-25 | 2016-11-23 | Univ Case Western Reserve | COMPOSITIONS AND METHODS FOR TREATING DEVELOPMENT INVASIVE DISORDERS |
WO2020264350A1 (en) * | 2019-06-26 | 2020-12-30 | The Regents Of The University Of California | Methods and compositions for treating smith-magenis syndrome |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4994467A (en) * | 1989-05-31 | 1991-02-19 | Zimmerman Andrew W | Treating autism and other developmental disorders in children with NMDA receptor antagonists |
JP2005500260A (en) * | 2001-04-02 | 2005-01-06 | ブラウン ユニバーシティ リサーチ ファウンデイション | Compositions and methods of use of mGluR5 antagonists |
US20080187492A1 (en) * | 2004-04-16 | 2008-08-07 | Mcbride Sean M J | Drosophila Models For Diseases Affecting Learning and Memory |
WO2006012403A1 (en) * | 2004-07-20 | 2006-02-02 | Massachusetts Institute Of Technology | Methods of treatment: cell signaling and glutamate release |
WO2006121919A2 (en) * | 2005-05-05 | 2006-11-16 | Massachusetts Institute Of Technology | Methods of treating obsessive compulsive disorder |
-
2006
- 2006-07-28 WO PCT/IB2006/002068 patent/WO2007029063A2/en active Application Filing
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008066750A1 (en) * | 2006-11-22 | 2008-06-05 | Seaside Therapeutics, Llc | Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism |
AU2007325836B2 (en) * | 2006-11-22 | 2011-07-21 | Clinical Research Associates, Llc | Methods of treating mental retardation, Down's syndrome, fragile X syndrome and autism |
US8143311B2 (en) | 2006-11-22 | 2012-03-27 | Seaside Therapeutics, Inc. | Methods of treating fragile X syndrome and autism |
US8273715B2 (en) | 2006-11-22 | 2012-09-25 | Seaside Therapeutics, Inc. | Methods of treating fragile X syndrome |
AU2011236093B2 (en) * | 2006-11-22 | 2012-10-18 | Clinical Research Associates, Llc | Methods of treating fragile x syndrome and autism |
US9044443B2 (en) | 2006-11-22 | 2015-06-02 | Clinical Research Associates, Llc | Methods of treating autism |
EP2948135A4 (en) * | 2013-01-25 | 2016-11-23 | Univ Case Western Reserve | COMPOSITIONS AND METHODS FOR TREATING DEVELOPMENT INVASIVE DISORDERS |
US10555916B2 (en) | 2013-01-25 | 2020-02-11 | Case Western Reserve University | NMDAR antagonist for the treatment of pervasive development disorders |
WO2020264350A1 (en) * | 2019-06-26 | 2020-12-30 | The Regents Of The University Of California | Methods and compositions for treating smith-magenis syndrome |
Also Published As
Publication number | Publication date |
---|---|
WO2007029063A3 (en) | 2007-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10555916B2 (en) | NMDAR antagonist for the treatment of pervasive development disorders | |
US5877173A (en) | Preventing neuronal degeneration in Alzheimer's disease | |
US5958919A (en) | Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration | |
Rudyk et al. | Chronic unpredictable stress influenced the behavioral but not the neurodegenerative impact of paraquat | |
US6391871B1 (en) | Preventing neuronal degeneration in Alzheimer's disease | |
Wong et al. | NMDA receptors in axons: there's no coincidence | |
Rodd-Henricks et al. | Effects of serotonin-3 receptor antagonists on the intracranial self-administration of ethanol within the ventral tegmental area of Wistar rats | |
Mohajeri et al. | The impact of genetic background on neurodegeneration and behavior in seizured mice | |
US20200121682A1 (en) | Compositions and methods for treatment of fragile x syndrome | |
KR20160078956A (en) | Methods of treating fragile x syndrome and related disorders | |
O’Connor et al. | Investigation of diazepam efficacy on anxiety-like behavior in hemiparkinsonian rats | |
WO2007029063A2 (en) | Treatment and/or prevention of pervasive developmental disorders | |
Clark et al. | Intranasal neuropeptide Y1 receptor antagonism improves motor deficits in symptomatic SOD1 ALS mice | |
Fijał et al. | Effects of serotonin (5-HT) 6 receptor ligands on responding for cocaine reward and seeking in rats | |
Erosa-Rivero et al. | The potency and efficacy of anticholinergics to inhibit haloperidol-induced catalepsy in rats correlates with their rank order of affinities for the muscarinic receptor subtypes | |
Takahashi et al. | Neurochemical and neuropharmacological characterization of ASP2905, a novel potent selective inhibitor of the potassium channel KCNH3 | |
US20220370388A1 (en) | Methods for treating microglial dysfunction | |
Inada et al. | Antisense hippocampal knockdown of NMDA-NR1 by HVJ-liposome vector induces deficit of prepulse inhibition but not of spatial memory | |
Hara et al. | Effect of YM872, a selective and highly water-soluble AMPA receptor antagonist, in the rat kindling and rekindling model of epilepsy | |
US20230017786A1 (en) | Dextromethadone as a disease-modifying treatment for neuropsychiatric disorders and diseases | |
US9851354B2 (en) | Methods of treating fragile X syndrome and related disorders | |
US20090221610A1 (en) | Compositions and Methods for Treating Cognitive Disorders | |
Taylor | Potassium channel dysfunction in the development of small vessel disease of the brain | |
Wang et al. | Dysfunction of EAAT3 enhances LPS-induced Postoperative Cognitive Dysfunction | |
Lovisari | microRNAs, gene networks, cell therapy: promises and challenges for treating epilepsies and their comorbidities |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC DATED 20.05.08 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06820723 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06820723 Country of ref document: EP Kind code of ref document: A2 |